Cross-linking	O
CD40	B-protein
on	O
B	B-cell_type
cells	I-cell_type
preferentially	O
induces	O
stress-activated	B-protein
protein	I-protein
kinases	I-protein
rather	O
than	O
mitogen-activated	B-protein
protein	I-protein
kinases	I-protein
.	O

The	O
B	B-protein
cell-associated	I-protein
surface	I-protein
molecule	I-protein
CD40	B-protein
plays	O
a	O
key	O
role	O
in	O
T	O
cell-dependent	O
B	O
cell	O
maturation	O
,	O
as	O
individuals	O
with	O
defects	O
in	O
either	O
CD40	B-protein
or	O
its	O
ligand	O
are	O
impaired	O
in	O
immunoglobulin	B-protein
isotype	O
class	O
switching	O
and	O
germinal	O
center	O
formation	O
.	O

CD40	B-protein
signaling	O
activates	O
downstream	B-protein
effectors	I-protein
,	O
including	O
the	O
tyrosine	B-protein
protein	I-protein
kinase	I-protein
,	O
Lyn	B-protein
,	O
the	O
phosphatidylinositol-3-kinase	B-protein
(	O
PI-3	B-protein
kinase	I-protein
)	O
,	O
and	O
the	O
transcription	O
factor	O
,	O
NF-kappa	B-protein
B	I-protein
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
stress-activated	B-protein
protein	I-protein
kinases	I-protein
(	O
SAPK	B-protein
)	O
are	O
activated	O
after	O
CD40	B-protein
cross-linking	O
on	O
various	O
B	B-cell_line
cell	I-cell_line
lines	I-cell_line
or	O
human	B-cell_type
tonsillar	I-cell_type
B	I-cell_type
cells	I-cell_type
.	O

The	O
activation	O
is	O
rapid	O
and	O
transient	O
and	O
is	O
mediated	O
through	O
a	O
cyclosporin	O
A-insensitive	O
pathway	O
.	O

Furthermore	O
,	O
this	O
signaling	O
pathway	O
appears	O
not	O
to	O
rely	O
on	O
protein	B-protein
kinase	I-protein
C	I-protein
.	O

While	O
CD40	B-protein
ligation	O
strongly	O
activates	O
the	O
SAPKs	B-protein
(	O
up	O
to	O
25-fold	O
)	O
,	O
it	O
does	O
not	O
affect	O
members	O
of	O
the	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
family	I-protein
(	O
MAPK	B-protein
;	O
ERK1	B-protein
and	O
ERK2	B-protein
)	O
.	O

Consistent	O
with	O
these	O
data	O
,	O
CD40	B-protein
signals	O
up-regulate	O
c-jun	B-RNA
but	I-RNA
not	I-RNA
c-fos	I-RNA
mRNA	I-RNA
and	O
alter	O
the	O
transcription	B-protein
factor	I-protein
ATF2	B-protein
but	O
not	O
the	O
Raf-1	B-protein
protein	I-protein
.	O

In	O
summary	O
,	O
CD40	B-protein
signaling	O
preferentially	O
induces	O
SAPK	B-protein
but	O
not	O
MAPK	B-protein
.	O

The	NULL
EMBO	NULL
Journal	NULL
vol.15	NULL
no.1	NULL
pp.92-101	NULL
,	NULL
1996	NULL
Cross-linking	NULL
CD40	NULL
on	NULL
B	NULL
cells	NULL
preferentially	NULL
induces	NULL
stress-activated	NULL
protein	NULL
kinases	NULL
rather	NULL
than	NULL
mitogen-activated	NULL
protein	NULL
kinases	NULL
Ingolf	NULL
Berberich	NULL
``	NULL
~	NULL
``	NULL
,	NULL
Geraldine	NULL
Shu	NULL
,	NULL
Friederike	NULL
Siebelt*	NULL
,	NULL
James	NULL
R.Woodgett®	NULL
,	NULL
John	NULL
M.Kyriakis®	NULL
and	NULL
Edward	NULL
A.Clark	NULL
!	NULL

*	NULL
'Department	NULL
of	NULL
Microbiology	NULL
,	NULL
SC-42	NULL
and	NULL
*Regional	NULL
Primate	NULL
Research	NULL
Center	NULL
,	NULL
University	NULL
of	NULL
Washington	NULL
Medical	NULL
Center	NULL
,	NULL
Seattle	NULL
,	NULL
WA	NULL
98195	NULL
,	NULL
USA	NULL
,	NULL
The	NULL
Ontario	NULL
Cancer	NULL
Institute	NULL
,	NULL
Princess	NULL
Margaret	NULL
Hospital	NULL
,	NULL
Toronto	NULL
,	NULL
Ontario	NULL
M4X	NULL
1K9	NULL
,	NULL
Canada	NULL
and	NULL
©Diabetes	NULL
Research	NULL
Laboratory	NULL
,	NULL
Massachusetts	NULL
General	NULL
Hospital	NULL
East	NULL
,	NULL
Charlestown	NULL
,	NULL
MA	NULL
02129	NULL
,	NULL
USA	NULL
*Present	NULL
address	NULL
:	NULL
Institut	NULL
fiir	NULL
Virologie	NULL
und	NULL
Immunbiologie	NULL
,	NULL
Universitit	NULL
Wiirzburg	NULL
,	NULL
Versbacher	NULL
Strasse	NULL
7	NULL
,	NULL
97078	NULL
Wiirzburg	NULL
,	NULL
Germany	NULL
Corresponding	NULL
author	NULL
The	NULL
B	NULL
cell-associated	NULL
surface	NULL
molecule	NULL
CD40	NULL
plays	NULL
a	NULL
key	NULL
role	NULL
in	NULL
T	NULL
cell-dependent	NULL
B	NULL
cell	NULL
maturation	NULL
,	NULL
as	NULL
individuals	NULL
with	NULL
defects	NULL
in	NULL
either	NULL
CD40	NULL
or	NULL
its	NULL
ligand	NULL
are	NULL
impaired	NULL
in	NULL
immunoglobulin	NULL
isotype	NULL
class	NULL
switching	NULL
and	NULL
germinal	NULL
center	NULL
formation	NULL
.	NULL

CD40	NULL
signaling	NULL
activates	NULL
downstream	NULL
effectors	NULL
,	NULL
including	NULL
the	NULL
tyrosine	NULL
protein	NULL
kinase	NULL
,	NULL
Lyn	NULL
,	NULL
the	NULL
phosphatidylinositol-3-kinase	NULL
(	NULL
PI-3	NULL
kinase	NULL
)	NULL
,	NULL
and	NULL
the	NULL
transcription	NULL
factor	NULL
,	NULL
NF-	NULL
<	NULL
B	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
demonstrate	NULL
that	NULL
stress-activated	NULL
protein	NULL
kinases	NULL
(	NULL
SAPK	NULL
)	NULL
are	NULL
activated	NULL
after	NULL
CD40	NULL
cross-linking	NULL
on	NULL
various	NULL
B	NULL
cell	NULL
lines	NULL
or	NULL
human	NULL
tonsillar	NULL
B	NULL
cells	NULL
.	NULL

The	NULL
activation	NULL
is	NULL
rapid	NULL
and	NULL
transient	NULL
and	NULL
is	NULL
mediated	NULL
through	NULL
a	NULL
cyclosporin	NULL
A-insensitive	NULL
pathway	NULL
.	NULL

Furthermore	NULL
,	NULL
this	NULL
signaling	NULL
pathway	NULL
appears	NULL
not	NULL
to	NULL
rely	NULL
on	NULL
protein	NULL
kinase	NULL
C.	NULL
While	NULL
CD40	NULL
ligation	NULL
strongly	NULL
activates	NULL
the	NULL
SAPKs	NULL
(	NULL
up	NULL
to	NULL
25-fold	NULL
)	NULL
,	NULL
it	NULL
does	NULL
not	NULL
affect	NULL
members	NULL
of	NULL
the	NULL
mitogen-activated	NULL
protein	NULL
kinase	NULL
family	NULL
(	NULL
MAPK	NULL
;	NULL
ERK1	NULL
and	NULL
ERK2	NULL
)	NULL
.	NULL

Consistent	NULL
with	NULL
these	NULL
data	NULL
,	NULL
CD40	NULL
signals	NULL
up-regulate	NULL
c-jun	NULL
but	NULL
not	NULL
c-fos	NULL
mRNA	NULL
and	NULL
alter	NULL
the	NULL
transcription	NULL
factor	NULL
ATF2	NULL
but	NULL
not	NULL
the	NULL
Raf-1	NULL
protein	NULL
.	NULL

In	NULL
summary	NULL
,	NULL
CD40	NULL
signaling	NULL
preferentially	NULL
induces	NULL
SAPK	NULL
but	NULL
not	NULL
MAPK	NULL
.	NULL

Keywords	NULL
:	NULL
B	NULL
cells/CD40/JNK/MAPK/SAPK	NULL
Introduction	NULL
CD40	NULL
is	NULL
a	NULL
45-50	NULL
kDa	NULL
transmembrane	NULL
glycoprotein	NULL
originally	NULL
identified	NULL
in	NULL
B	NULL
cells	NULL
,	NULL
some	NULL
B	NULL
cell	NULL
malignancies	NULL
and	NULL
carcinoma	NULL
cell	NULL
lines	NULL
(	NULL
Paulie	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1985	NULL
;	NULL
Clark	NULL
and	NULL
Ledbetter	NULL
,	NULL
1986	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
B	NULL
cells	NULL
,	NULL
CD40	NULL
has	NULL
also	NULL
been	NULL
detected	NULL
in	NULL
other	NULL
cell	NULL
types	NULL
,	NULL
including	NULL
follicular	NULL
dendritic	NULL
cells	NULL
(	NULL
Schriever	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
,	NULL
dendritic	NULL
cells	NULL
(	NULL
Hart	NULL
and	NULL
McKenzie	NULL
,	NULL
1988	NULL
)	NULL
,	NULL
activated	NULL
macrophages	NULL
(	NULL
Alderson	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
and	NULL
thymic	NULL
epithelial	NULL
cells	NULL
(	NULL
Galy	NULL
and	NULL
Spits	NULL
,	NULL
1992	NULL
)	NULL
.	NULL

It	NULL
is	NULL
a	NULL
member	NULL
of	NULL
the	NULL
tumor	NULL
necrosis	NULL
factor	NULL
(	NULL
TNF	NULL
)	NULL
receptor	NULL
superfamily	NULL
(	NULL
Smith	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

The	NULL
ligand	NULL
for	NULL
CD40	NULL
(	NULL
CD4O0L	NULL
,	NULL
also	NULL
known	NULL
as	NULL
gp39	NULL
,	NULL
T-BAM	NULL
or	NULL
TRAP	NULL
)	NULL
is	NULL
expressed	NULL
on	NULL
activated	NULL
CD4¢*	NULL
T	NULL
cells	NULL
(	NULL
Armitage	NULL
er	NULL
a/	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
.	NULL

Contact-dependent	NULL
signals	NULL
mediated	NULL
through	NULL
CD40/CD4OL	NULL
stimulate	NULL
B	NULL
cell	NULL
survival	NULL
,	NULL
92	NULL
growth	NULL
and	NULL
differentiation	NULL
(	NULL
Noelle	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1992	NULL
;	NULL
Tsubata	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
;	NULL
Klaus	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994b	NULL
;	NULL
Parry	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

The	NULL
key	NULL
role	NULL
of	NULL
CD40	NULL
in	NULL
the	NULL
humoral	NULL
immune	NULL
response	NULL
is	NULL
evident	NULL
from	NULL
patients	NULL
with	NULL
X-linked	NULL
hyper-IgM	NULL
syndrome	NULL
(	NULL
HIM	NULL
)	NULL
,	NULL
where	NULL
the	NULL
cooperation	NULL
between	NULL
B	NULL
and	NULL
T	NULL
cells	NULL
has	NULL
been	NULL
disturbed	NULL
due	NULL
to	NULL
a	NULL
defective	NULL
CD4O0L	NULL
gene	NULL
(	NULL
Hill	NULL
and	NULL
Chapel	NULL
,	NULL
1993	NULL
)	NULL
.	NULL

These	NULL
patients	NULL
do	NULL
not	NULL
form	NULL
germinal	NULL
centers	NULL
and	NULL
do	NULL
not	NULL
switch	NULL
from	NULL
producing	NULL
IgM	NULL
to	NULL
other	NULL
Ig	NULL
classes	NULL
.	NULL

A	NULL
similar	NULL
phenotype	NULL
has	NULL
been	NULL
found	NULL
in	NULL
mice	NULL
with	NULL
targeted	NULL
disruption	NULL
of	NULL
either	NULL
the	NULL
CD40	NULL
(	NULL
Kawabe	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
or	NULL
the	NULL
CD40L	NULL
(	NULL
Xu	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
gene	NULL
.	NULL

CD40	NULL
plays	NULL
a	NULL
critical	NULL
role	NULL
in	NULL
activation	NULL
,	NULL
proliferation	NULL
and	NULL
differentiation	NULL
of	NULL
B	NULL
cells	NULL
,	NULL
including	NULL
immediate	NULL
early	NULL
gene	NULL
expression	NULL
,	NULL
cell	NULL
adhesion	NULL
,	NULL
interleukin	NULL
(	NULL
IL	NULL
)	NULL
-6	NULL
secretion	NULL
,	NULL
B	NULL
cell	NULL
proliferation	NULL
and	NULL
survival	NULL
,	NULL
and	NULL
Ig	NULL
isotype	NULL
production	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
crosslinking	NULL
CD40	NULL
promotes	NULL
the	NULL
survival	NULL
of	NULL
germinal	NULL
center	NULL
B	NULL
cells	NULL
and	NULL
,	NULL
in	NULL
combination	NULL
with	NULL
IL-4	NULL
,	NULL
supports	NULL
long-term	NULL
B	NULL
cell	NULL
proliferation	NULL
(	NULL
see	NULL
Banchereau	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
Clark	NULL
and	NULL
Ledbetter	NULL
,	NULL
1994	NULL
;	NULL
Klaus	NULL
er	NULL
al	NULL
.	NULL

,	NULL
1994a	NULL
)	NULL
.	NULL

It	NULL
may	NULL
also	NULL
function	NULL
to	NULL
regulate	NULL
dendritic	NULL
cells	NULL
and	NULL
dendritic	NULL
cell-dependent	NULL
HIV-1	NULL
expression	NULL
(	NULL
Pinchuk	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

New	NULL
protein	NULL
tyrosine	NULL
phosphorylation	NULL
is	NULL
induced	NULL
very	NULL
early	NULL
after	NULL
CD40	NULL
stimulation	NULL
(	NULL
Uckun	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
;	NULL
Knox	NULL
and	NULL
Gordon	NULL
,	NULL
1993	NULL
;	NULL
Faris	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
Ren	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
and	NULL
is	NULL
accompanied	NULL
by	NULL
an	NULL
increase	NULL
in	NULL
Lyn	NULL
protein	NULL
tyrosine	NULL
kinase	NULL
activity	NULL
and	NULL
phosphatidylinositol-3-kinase	NULL
(	NULL
Pl-3	NULL
kinase	NULL
)	NULL
activity	NULL
(	NULL
Ren	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

We	NULL
and	NULL
others	NULL
have	NULL
found	NULL
that	NULL
CD40	NULL
ligation	NULL
induces	NULL
NF-KB	NULL
(	NULL
Berberich	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
Francis	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

Recently	NULL
,	NULL
protein	NULL
(	NULL
s	NULL
)	NULL
that	NULL
interact	NULL
directly	NULL
with	NULL
the	NULL
CD40	NULL
cytoplasmic	NULL
tail	NULL
(	NULL
called	NULL
CD4O0bp	NULL
,	NULL
CRAFl	NULL
and	NULL
LAP1	NULL
)	NULL
have	NULL
been	NULL
described	NULL
by	NULL
several	NULL
investigators	NULL
(	NULL
Hu	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
Cheng	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
;	NULL
Mosialos	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

Although	NULL
the	NULL
exact	NULL
function	NULL
of	NULL
CD40	NULL
receptor-associated	NULL
factor	NULL
,	NULL
CRAFI	NULL
,	NULL
is	NULL
not	NULL
known	NULL
,	NULL
an	NULL
essential	NULL
role	NULL
for	NULL
this	NULL
protein	NULL
in	NULL
CD40	NULL
signaling	NULL
has	NULL
been	NULL
demonstrated	NULL
in	NULL
a	NULL
B	NULL
cell	NULL
line	NULL
expressing	NULL
a	NULL
truncated	NULL
version	NULL
of	NULL
CRAFIL	NULL
.	NULL

These	NULL
cells	NULL
no	NULL
longer	NULL
up-regulate	NULL
.	NULL

CD23	NULL
,	NULL
a	NULL
low	NULL
affinity	NULL
Fc	NULL
receptor	NULL
for	NULL
IgE	NULL
,	NULL
after	NULL
signaling	NULL
through	NULL
CD40	NULL
(	NULL
Cheng	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

Whether	NULL
this	NULL
binding	NULL
protein	NULL
relays	NULL
all	NULL
signals	NULL
to	NULL
account	NULL
for	NULL
all	NULL
phenotypic	NULL
changes	NULL
remains	NULL
to	NULL
be	NULL
established	NULL
.	NULL

Stress-activated	NULL
protein	NULL
kinases	NULL
(	NULL
SAPK	NULL
;	NULL
also	NULL
known	NULL
as	NULL
JNK	NULL
for	NULL
c-Jun	NULL
NH	NULL
»	NULL
-terminal	NULL
kinase	NULL
)	NULL
,	NULL
form	NULL
a	NULL
group	NULL
of	NULL
serine-threonine	NULL
protein	NULL
kinases	NULL
(	NULL
see	NULL
Davis	NULL
,	NULL
1994	NULL
)	NULL
related	NULL
to	NULL
the	NULL
mitogen-activated	NULL
protein	NULL
kinases	NULL
(	NULL
MAPK	NULL
;	NULL
ERK	NULL
1	NULL
and	NULL
ERK2	NULL
)	NULL
.	NULL

Different	NULL
isoforms	NULL
of	NULL
these	NULL
kinases-with	NULL
molecular	NULL
weights	NULL
of	NULL
46	NULL
(	NULL
p46	NULL
)	NULL
or	NULL
54	NULL
kDa	NULL
(	NULL
pS4	NULL
)	NULL
-have	NULL
been	NULL
cloned	NULL
recently	NULL
(	NULL
Dérijard	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
Kyriakis	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
Sluss	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
refer	NULL
to	NULL
the	NULL
p46	NULL
SAPKs	NULL
as	NULL
SAPKs	NULL
.	NULL

Like	NULL
ERK1	NULL
and	NULL
ERK2	NULL
,	NULL
they	NULL
are	NULL
activated	NULL
through	NULL
phosphorylation	NULL
of	NULL
both	NULL
a	NULL
threonine	NULL
and	NULL
tyrosine	NULL
residue	NULL
in	NULL
a	NULL
highly	NULL
conserved	NULL
tripeptide	NULL
motif	NULL
(	NULL
Dérijard	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

Environmental	NULL
stress	NULL
,	NULL
TNF-	NULL
,	NULL
IL-1	NULL
and	NULL
certain	NULL
growth	NULL
factors	NULL
[	NULL
i.e	NULL
.	NULL

epidermal	NULL
growth	NULL
factor	NULL
©	NULL
Oxford	NULL
University	NULL
Press	NULL
«	NULL
0	NULL
:	NULL
dre	NULL
Cross-linking	NULL
CD40	NULL
activates	NULL
SAPK	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Cross-linking	NULL
CD40	NULL
activates	NULL
SAPK	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Daudi	NULL
cells	NULL
were	NULL
stimulated	NULL
for	NULL
15	NULL
min	NULL
as	NULL
indicated	NULL
with	NULL
anti-CD40	NULL
mAb	NULL
(	NULL
0.5	NULL
ug/ml	NULL
)	NULL
or	NULL
PMA	NULL
(	NULL
P	NULL
,	NULL
50	NULL
ng/ml	NULL
)	NULL
and	NULL
ionomycin	NULL
(	NULL
I	NULL
,	NULL
0.25	NULL
ug/ml	NULL
)	NULL
.	NULL

SAPK	NULL
were	NULL
precipitated	NULL
from	NULL
the	NULL
cell	NULL
lysates	NULL
and	NULL
tested	NULL
for	NULL
activity	NULL
in	NULL
an	NULL
immune	NULL
complex	NULL
in	NULL
vitro	NULL
kinase	NULL
assay	NULL
using	NULL
GST-c-Jun	NULL
(	NULL
2	NULL
ug	NULL
)	NULL
as	NULL
substrate	NULL
.	NULL

In	NULL
control	NULL
(	NULL
con	NULL
.	NULL
)	NULL

lanes	NULL
,	NULL
a	NULL
control	NULL
antiserum	NULL
(	NULL
anti-rac2	NULL
)	NULL
was	NULL
used	NULL
in	NULL
the	NULL
precipitation	NULL
step	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Daudi	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
either	NULL
anti-CD3	NULL
(	NULL
-	NULL
)	NULL
or	NULL
anti-CD40	NULL
(	NULL
+	NULL
)	NULL
mAb	NULL
(	NULL
0.5	NULL
ug/ml	NULL
)	NULL
for	NULL
15	NULL
min	NULL
.	NULL

(	NULL
a	NULL
)	NULL
The	NULL
substrate	NULL
specificity	NULL
of	NULL
the	NULL
precipitated	NULL
SAPK	NULL
was	NULL
tested	NULL
using	NULL
GST	NULL
fusion	NULL
proteins	NULL
or	NULL
MBP	NULL
as	NULL
indicated	NULL
in	NULL
an	NULL
immune	NULL
complex	NULL
kinase	NULL
assay	NULL
.	NULL

(	NULL
b	NULL
)	NULL
The	NULL
Coomassie	NULL
Blue	NULL
staining	NULL
of	NULL
the	NULL
gel	NULL
.	NULL

Ab	NULL
,	NULL
precipitating	NULL
antibodies	NULL
.	NULL

(	NULL
EGF	NULL
)	NULL
and	NULL
nerve	NULL
growth	NULL
factor	NULL
(	NULL
NGF	NULL
)	NULL
]	NULL
are	NULL
potent	NULL
activa-tors	NULL
of	NULL
SAPKs	NULL
(	NULL
Hibi	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
;	NULL
Bird	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
Dérijard	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
Kyriakis	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
Minden	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994b	NULL
)	NULL
.	NULL

Activation	NULL
of	NULL
SAPK	NULL
probably	NULL
involves	NULL
Ras-dependent	NULL
and	NULL
Ras-independent	NULL
pathways	NULL
(	NULL
Minden	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1994a	NULL
)	NULL
.	NULL

MEKK	NULL
(	NULL
Yan	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
,	NULL
a	NULL
MAPK	NULL
kinase	NULL
kinase	NULL
,	NULL
seems	NULL
to	NULL
be	NULL
a	NULL
good	NULL
candidate	NULL
for	NULL
transmitting	NULL
the	NULL
activation	NULL
signal	NULL
to	NULL
SEK	NULL
1	NULL
,	NULL
an	NULL
immediate	NULL
upstream	NULL
regulator	NULL
of	NULL
SAPK	NULL
(	NULL
Sanchez	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

The	NULL
regulation	NULL
of	NULL
SAPK	NULL
and	NULL
MAPK	NULL
can	NULL
be	NULL
both	NULL
linked	NULL
and	NULL
executed	NULL
separately	NULL
.	NULL

While	NULL
EGF	NULL
activates	NULL
both	NULL
the	NULL
SAPKs	NULL
and	NULL
MAPKs	NULL
(	NULL
Minden	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994a	NULL
)	NULL
,	NULL
TNF-a	NULL
and	NULL
UV	NULL
radiation	NULL
target	NULL
SAPKs	NULL
much	NULL
more	NULL
efficiently	NULL
(	NULL
Kyriakis	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
Minden	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994a	NULL
)	NULL
.	NULL

The	NULL
transcription	NULL
factors	NULL
c-Jun	NULL
and	NULL
ATF2	NULL
are	NULL
the	NULL
best	NULL
characterized	NULL
substrates	NULL
for	NULL
SAPK	NULL
to	NULL
date	NULL
.	NULL

In	NULL
both	NULL
cases	NULL
,	NULL
two	NULL
serines	NULL
located	NULL
proximal	NULL
to	NULL
the	NULL
major	NULL
transactivation	NULL
domain	NULL
become	NULL
phosphorylated	NULL
in	NULL
response	NULL
to	NULL
SAPK	NULL
agonists	NULL
(	NULL
Hibi	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
;	NULL
Gupta	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

In	NULL
the	NULL
study	NULL
reported	NULL
here	NULL
,	NULL
we	NULL
investigated	NULL
whether	NULL
CD40	NULL
signaling	NULL
can	NULL
modulate	NULL
SAPK	NULL
and/or	NULL
MAPK	NULL
activi-ties	NULL
.	NULL

Our	NULL
results	NULL
indicate	NULL
that	NULL
cross-linking	NULL
CD40	NULL
on	NULL
B	NULL
cells	NULL
strongly	NULL
activates	NULL
SAPK	NULL
but	NULL
changes	NULL
MAPK	NULL
activity	NULL
only	NULL
marginally	NULL
,	NULL
if	NULL
at	NULL
all	NULL
.	NULL

Results	NULL
Cross-linking	NULL
CD40	NULL
on	NULL
B	NULL
cells	NULL
activates	NULL
SAPK	NULL
Initially	NULL
,	NULL
the	NULL
effect	NULL
of	NULL
cross-linking	NULL
CD40	NULL
on	NULL
SAPK	NULL
(	NULL
p46	NULL
,	NULL
JNK	NULL
1	NULL
)	NULL
activity	NULL
was	NULL
examined	NULL
in	NULL
the	NULL
human	NULL
B	NULL
cell	NULL
lymphoma	NULL
line	NULL
,	NULL
Daudi	NULL
.	NULL

The	NULL
activity	NULL
of	NULL
the	NULL
SAPK	NULL
after	NULL
various	NULL
stimuli	NULL
was	NULL
evaluated	NULL
in	NULL
immune	NULL
complex	NULL
kinase	NULL
assays	NULL
using	NULL
a	NULL
GST-c-Jun	NULL
(	NULL
amino	NULL
acids	NULL
5-89	NULL
)	NULL
fusion	NULL
protein	NULL
as	NULL
substrate	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Figure	NULL
1A	NULL
,	NULL
cross-linking	NULL
CD40	NULL
strongly	NULL
activated	NULL
SAPK	NULL
,	NULL
whereas	NULL
treating	NULL
the	NULL
Daudi	NULL
cells	NULL
with	NULL
several	NULL
isotype-matched	NULL
control	NULL
anti-bodies-either	NULL
binding	NULL
(	NULL
anti-CD22	NULL
and	NULL
anti-CD37	NULL
)	NULL
or	NULL
non-binding	NULL
(	NULL
anti-CD3	NULL
)	NULL
-did	NULL
not	NULL
influence	NULL
the	NULL
activity	NULL
of	NULL
SAPK	NULL
compared	NULL
with	NULL
the	NULL
medium	NULL
control	NULL
.	NULL

Next	NULL
,	NULL
we	NULL
tested	NULL
the	NULL
substrate	NULL
specificity	NULL
of	NULL
the	NULL
anti-SAPK	NULL
precipitates	NULL
.	NULL

Whereas	NULL
GST-c-Jun	NULL
containing	NULL
both	NULL
the	NULL
phosphorylation	NULL
sites	NULL
(	NULL
Ser63	NULL
and	NULL
Ser73	NULL
)	NULL
and	NULL
the	NULL
d	NULL
domain	NULL
as	NULL
binding	NULL
domain	NULL
for	NULL
SAPK	NULL
was	NULL
phosphorylated	NULL
,	NULL
none	NULL
of	NULL
the	NULL
other	NULL
substrates	NULL
tested	NULL
was	NULL
phosphorylated	NULL
by	NULL
the	NULL
anti-SAPK	NULL
precipitates	NULL
(	NULL
Figure	NULL
1B	NULL
)	NULL
.	NULL

Most	NULL
importantly	NULL
,	NULL
a	NULL
GST-c-Jun	NULL
fusion	NULL
protein	NULL
containing	NULL
both	NULL
phosphorylation	NULL
sites	NULL
but	NULL
lacking	NULL
the	NULL
8	NULL
domain	NULL
(	NULL
GST-c-Jun/nb	NULL
)	NULL
,	NULL
previously	NULL
shown	NULL
to	NULL
be	NULL
necessary	NULL
for	NULL
SAPK-dependent	NULL
c-Jun	NULL
phosphorylation	NULL
(	NULL
Adler	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
;	NULL
Hibi	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
;	NULL
Dérijard	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
,	NULL
and	NULL
myelin	NULL
basic	NULL
protein	NULL
(	NULL
MBP	NULL
;	NULL
a	NULL
substrate	NULL
for	NULL
ERK	NULL
!	NULL

and	NULL
ERK2	NULL
)	NULL
could	NULL
not	NULL
serve	NULL
as	NULL
substrates	NULL
for	NULL
SAPK	NULL
precipitates	NULL
in	NULL
immune	NULL
complex	NULL
kinase	NULL
assays	NULL
(	NULL
Figure	NULL
1B	NULL
)	NULL
.	NULL

Next	NULL
,	NULL
we	NULL
determined	NULL
the	NULL
kinetics	NULL
of	NULL
SAPK	NULL
activation	NULL
after	NULL
CD40	NULL
cross-linking	NULL
on	NULL
Daudi	NULL
cells	NULL
.	NULL

SAPK	NULL
activity	NULL
was	NULL
increased	NULL
10-	NULL
to	NULL
20-fold	NULL
compared	NULL
with	NULL
unstimulated	NULL
cells	NULL
within	NULL
5	NULL
min	NULL
after	NULL
the	NULL
onset	NULL
of	NULL
signaling	NULL
through	NULL
CD40	NULL
,	NULL
reached	NULL
its	NULL
maximum	NULL
(	NULL
>	NULL
20	NULL
fold	NULL
)	NULL
after	NULL
10-15	NULL
min	NULL
,	NULL
and	NULL
declined	NULL
steadily	NULL
thereafter	NULL
(	NULL
Figure	NULL
2A-C	NULL
)	NULL
.	NULL

Similar	NULL
activation	NULL
of	NULL
SAPK	NULL
was	NULL
seen	NULL
when	NULL
soluble	NULL
CD4O0L	NULL
was	NULL
used	NULL
to	NULL
ligate	NULL
CD40	NULL
on	NULL
Daudi	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
kinetics	NULL
of	NULL
activation	NULL
were	NULL
independent	NULL
of	NULL
the	NULL
kinase	NULL
assay	NULL
used	NULL
,	NULL
i.e	NULL
.	NULL

in	NULL
vitro	NULL
immune	NULL
complex	NULL
kinase	NULL
assays	NULL
and	NULL
in	NULL
vitro	NULL
in-gel	NULL
kinase	NULL
assays	NULL
gave	NULL
comparable	NULL
results	NULL
93	NULL
1.Berberich	NULL
et	NULL
a/	NULL
.	NULL

Fig	NULL
.	NULL

2	NULL
.	NULL

Cross-linking	NULL
CD40	NULL
transiently	NULL
activates	NULL
SAPK	NULL
in	NULL
Daudi	NULL
cells	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Daudi	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
medium	NULL
or	NULL
anti-CD3	NULL
or	NULL
anti-CD40	NULL
mAb	NULL
(	NULL
0.5	NULL
ug/ml	NULL
)	NULL
.	NULL

The	NULL
activities	NULL
of	NULL
the	NULL
SAPKs	NULL
were	NULL
determined	NULL
in	NULL
an	NULL
immune	NULL
complex	NULL
kinase	NULL
assay	NULL
using	NULL
GST-c-Jun	NULL
(	NULL
2	NULL
ug	NULL
)	NULL
as	NULL
substrate	NULL
.	NULL

Activation	NULL
(	NULL
fold	NULL
ind	NULL
.	NULL
)	NULL

of	NULL
the	NULL
SAPK	NULL
in	NULL
anti-CD40-stimulated	NULL
versus	NULL
control	NULL
cells	NULL
was	NULL
evaluated	NULL
by	NULL
a	NULL
PhosphorImager	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Daudi	NULL
cells	NULL
were	NULL
stimulated	NULL
as	NULL
in	NULL
(	NULL
A	NULL
)	NULL
.	NULL

SAPKs	NULL
were	NULL
precipitated	NULL
from	NULL
the	NULL
lysates	NULL
and	NULL
tested	NULL
for	NULL
their	NULL
activity	NULL
in	NULL
an	NULL
in-gel	NULL
kinase	NULL
assay	NULL
using	NULL
GST-c-Jun	NULL
as	NULL
substrate	NULL
(	NULL
40	NULL
ug/ml	NULL
)	NULL
.	NULL

In	NULL
the	NULL
control	NULL
lane	NULL
(	NULL
con	NULL
.	NULL
)	NULL

,	NULL
1/7	NULL
of	NULL
each	NULL
of	NULL
the	NULL
other	NULL
lysates	NULL
was	NULL
combined	NULL
,	NULL
immunoprecipitated	NULL
with	NULL
anti-rac2	NULL
antisera	NULL
(	NULL
*	NULL
)	NULL
as	NULL
control	NULL
antisera	NULL
and	NULL
tested	NULL
in	NULL
parallel	NULL
with	NULL
the	NULL
other	NULL
samples	NULL
.	NULL

Fold	NULL
induction	NULL
was	NULL
assessed	NULL
as	NULL
in	NULL
(	NULL
A	NULL
)	NULL
.	NULL

Molecular	NULL
weight	NULL
standards	NULL
are	NULL
indicated	NULL
in	NULL
kDa	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Daudi	NULL
cells	NULL
were	NULL
stimulated	NULL
as	NULL
in	NULL
(	NULL
A	NULL
)	NULL
.	NULL

SAPKs	NULL
were	NULL
precipitated	NULL
from	NULL
the	NULL
cytoplasmic	NULL
extracts	NULL
and	NULL
tested	NULL
for	NULL
their	NULL
activity	NULL
in	NULL
immune	NULL
complex	NULL
kinase	NULL
assays	NULL
as	NULL
in	NULL
(	NULL
A	NULL
)	NULL
(	NULL
panel	NULL
a	NULL
)	NULL
.	NULL

The	NULL
nuclear	NULL
extracts	NULL
of	NULL
the	NULL
same	NULL
cells	NULL
were	NULL
tested	NULL
for	NULL
induction	NULL
of	NULL
NF-xB	NULL
binding	NULL
activity	NULL
in	NULL
an	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
using	NULL
the	NULL
NF-KB	NULL
binding	NULL
site	NULL
found	NULL
in	NULL
the	NULL
promoter	NULL
of	NULL
invariant	NULL
chain	NULL
of	NULL
MHC	NULL
class	NULL
II	NULL
(	NULL
Pessara	NULL
er	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
(	NULL
panel	NULL
b	NULL
)	NULL
.	NULL

(	NULL
Figure	NULL
2A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

The	NULL
results	NULL
of	NULL
the	NULL
in-gel	NULL
kinase	NULL
assays	NULL
further	NULL
support	NULL
the	NULL
specificity	NULL
of	NULL
the	NULL
antiserum	NULL
used	NULL
because	NULL
:	NULL
(	NULL
i	NULL
)	NULL
the	NULL
molecular	NULL
weight	NULL
detected	NULL
for	NULL
SAPK	NULL
correlates	NULL
well	NULL
with	NULL
that	NULL
published	NULL
for	NULL
SAPK	NULL
(	NULL
46	NULL
kDa	NULL
)	NULL
(	NULL
Hibi	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
;	NULL
Dérijard	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
Kyriakis	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
;	NULL
(	NULL
ii	NULL
)	NULL
only	NULL
one	NULL
dominant	NULL
band	NULL
emerged	NULL
in	NULL
the	NULL
autoradiograph	NULL
(	NULL
Figure	NULL
2B	NULL
)	NULL
;	NULL
and	NULL
(	NULL
iii	NULL
)	NULL
an	NULL
anti-rac2	NULL
antiserum	NULL
used	NULL
as	NULL
a	NULL
control	NULL
gave	NULL
no	NULL
signal	NULL
(	NULL
Figure	NULL
2B	NULL
)	NULL
.	NULL

While	NULL
anti-CD40	NULL
strongly	NULL
activated	NULL
p46	NULL
SAPK	NULL
(	NULL
JNK	NULL
1	NULL
)	NULL
in	NULL
Daudi	NULL
cells	NULL
,	NULL
it	NULL
only	NULL
weakly	NULL
and	NULL
transiently	NULL
activated	NULL
p54	NULL
SAPK	NULL
(	NULL
JNK2	NULL
)	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Recently	NULL
,	NULL
we	NULL
and	NULL
others	NULL
have	NULL
shown	NULL
that	NULL
CD40	NULL
ligation	NULL
activates	NULL
the	NULL
NF-KB	NULL
system	NULL
(	NULL
Berberich	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
Francis	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

Since	NULL
it	NULL
is	NULL
conceivable	NULL
that	NULL
SAPK	NULL
is	NULL
involved	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
these	NULL
transcription	NULL
factors	NULL
,	NULL
we	NULL
also	NULL
analyzed	NULL
the	NULL
onset	NULL
of	NULL
SAPK	NULL
relative	NULL
to	NULL
the	NULL
activation	NULL
of	NULL
NF-KB	NULL
after	NULL
CD40	NULL
ligation	NULL
.	NULL

SAPK	NULL
slightly	NULL
preceded	NULL
the	NULL
induction	NULL
of	NULL
NF-KB	NULL
binding	NULL
activity	NULL
in	NULL
Daudi	NULL
cells	NULL
(	NULL
Figure	NULL
2C	NULL
)	NULL
.	NULL

We	NULL
next	NULL
tested	NULL
whether	NULL
SAPK	NULL
activation	NULL
after	NULL
CD40	NULL
cross-linking	NULL
could	NULL
be	NULL
generalized	NULL
to	NULL
other	NULL
B	NULL
cell	NULL
sources	NULL
.	NULL

Cross-linking	NULL
CD40	NULL
was	NULL
also	NULL
sufficient	NULL
to	NULL
induce	NULL
SAPK	NULL
activity	NULL
in	NULL
the	NULL
murine	NULL
B	NULL
cell	NULL
lymphoma	NULL
M12	NULL
(	NULL
Figure	NULL
3A	NULL
)	NULL
and	NULL
the	NULL
murine	NULL
immature	NULL
B	NULL
cell	NULL
,	NULL
WEHI	NULL
231	NULL
(	NULL
Figure	NULL
3B	NULL
)	NULL
.	NULL

As	NULL
in	NULL
Daudi	NULL
cells	NULL
,	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
p54	NULL
SAPK	NULL
(	NULL
JINK2	NULL
)	NULL
isoform	NULL
was	NULL
weak	NULL
and	NULL
very	NULL
transient	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
in	NULL
a	NULL
variant	NULL
of	NULL
M12	NULL
stably	NULL
transfected	NULL
with	NULL
human	NULL
CD40	NULL
(	NULL
M12/CD40	NULL
)	NULL
,	NULL
both	NULL
human	NULL
and	NULL
murine	NULL
CD40	NULL
molecules	NULL
initiated	NULL
SAPK	NULL
activation	NULL
,	NULL
indicating	NULL
that	NULL
the	NULL
CD40-SAPK	NULL
signaling	NULL
pathway	NULL
is	NULL
evolutionarily	NULL
conserved	NULL
(	NULL
Figure	NULL
3A	NULL
)	NULL
.	NULL

The	NULL
B	NULL
cell	NULL
lines	NULL
tested	NULL
varied	NULL
in	NULL
the	NULL
strength	NULL
of	NULL
94	NULL
SAPK	NULL
activity	NULL
induced	NULL
through	NULL
CD40	NULL
;	NULL
for	NULL
example	NULL
,	NULL
CD40	NULL
ligation	NULL
produced	NULL
only	NULL
2-fold	NULL
induction	NULL
of	NULL
SAPK	NULL
activity	NULL
in	NULL
DND39	NULL
and	NULL
CESS	NULL
cell	NULL
lines	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

We	NULL
also	NULL
examined	NULL
human	NULL
tonsillar	NULL
B	NULL
cells	NULL
for	NULL
their	NULL
responsiveness	NULL
to	NULL
CD40	NULL
signaling	NULL
.	NULL

Unlike	NULL
the	NULL
B	NULL
cell	NULL
lines	NULL
tested	NULL
,	NULL
which	NULL
gave	NULL
highly	NULL
reproducible	NULL
results	NULL
,	NULL
the	NULL
freshly	NULL
isolated	NULL
human	NULL
tonsillar	NULL
B	NULL
cells	NULL
yielded	NULL
results	NULL
that	NULL
varied	NULL
from	NULL
donor	NULL
to	NULL
donor	NULL
.	NULL

In	NULL
~50	NULL
%	NULL
of	NULL
all	NULL
experiments	NULL
,	NULL
crosslinking	NULL
CD40	NULL
alone	NULL
was	NULL
sufficient	NULL
to	NULL
activate	NULL
SAPK	NULL
.	NULL

In	NULL
most	NULL
of	NULL
these	NULL
experiments	NULL
,	NULL
the	NULL
activation	NULL
was	NULL
2-	NULL
to	NULL
4-fold	NULL
but	NULL
ranged	NULL
as	NULL
high	NULL
as	NULL
12-fold	NULL
over	NULL
the	NULL
medium	NULL
controls	NULL
(	NULL
Figure	NULL
3C	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
other	NULL
experiments	NULL
,	NULL
cross-linking	NULL
CD40	NULL
was	NULL
not	NULL
sufficient	NULL
to	NULL
stimulate	NULL
SAPK	NULL
activity	NULL
in	NULL
untreated	NULL
cells	NULL
(	NULL
Figure	NULL
3D	NULL
)	NULL
.	NULL

This	NULL
suggested	NULL
that	NULL
the	NULL
state	NULL
of	NULL
activation	NULL
of	NULL
the	NULL
B	NULL
cells	NULL
might	NULL
influence	NULL
their	NULL
response	NULL
to	NULL
CD40	NULL
ligation	NULL
and	NULL
the	NULL
degree	NULL
of	NULL
SAPK	NULL
activation	NULL
.	NULL

To	NULL
test	NULL
this	NULL
possibility	NULL
,	NULL
we	NULL
kept	NULL
tonsillar	NULL
cells	NULL
in	NULL
medium	NULL
or	NULL
pre-treated	NULL
them	NULL
with	NULL
a	NULL
low	NULL
dose	NULL
of	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
(	NULL
PMA	NULL
)	NULL
for	NULL
12	NULL
h	NULL
before	NULL
isolating	NULL
the	NULL
B	NULL
cells	NULL
.	NULL

Pre-treatment	NULL
with	NULL
PMA	NULL
consistently	NULL
made	NULL
tonsillar	NULL
B	NULL
cells	NULL
more	NULL
responsive	NULL
to	NULL
CD40-mediated	NULL
SAPK	NULL
activation	NULL
(	NULL
Figure	NULL
3D	NULL
)	NULL
.	NULL

CD40	NULL
signaling	NULL
preferentially	NULL
targets	NULL
SAPK	NULL
compared	NULL
with	NULL
ERK1	NULL
and	NULL
ERK2	NULL
Next	NULL
,	NULL
we	NULL
asked	NULL
whether	NULL
CD40	NULL
ligation	NULL
could	NULL
also	NULL
activate	NULL
the	NULL
related	NULL
protein	NULL
kinases	NULL
ERK1	NULL
and	NULL
ERK2	NULL
,	NULL
initially	NULL
using	NULL
the	NULL
Daudi	NULL
B	NULL
cell	NULL
line	NULL
.	NULL

Under	NULL
conditions	NULL
in	NULL
which	NULL
CD40	NULL
ligation	NULL
clearly	NULL
activated	NULL
SAPK	NULL
,	NULL
the	NULL
activity	NULL
of	NULL
ERK1	NULL
and	NULL
ERK2	NULL
was	NULL
not	NULL
changed	NULL
as	NULL
measured	NULL
by	NULL
the	NULL
Cross-linking	NULL
CD40	NULL
activates	NULL
SAPK	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

Cross-linking	NULL
CD40	NULL
activates	NULL
SAPK	NULL
in	NULL
murine	NULL
B	NULL
cell	NULL
lines	NULL
and	NULL
human	NULL
tonsillar	NULL
B	NULL
cells	NULL
.	NULL

(	NULL
A-C	NULL
)	NULL
The	NULL
murine	NULL
B	NULL
cell	NULL
lymphoma	NULL
M12	NULL
(	NULL
wild-type	NULL
,	NULL
M12	NULL
)	NULL
or	NULL
a	NULL
clone	NULL
stably	NULL
transfected	NULL
with	NULL
human	NULL
CD40	NULL
(	NULL
M12/CDA40	NULL
)	NULL
(	NULL
A	NULL
)	NULL
,	NULL
the	NULL
murine	NULL
immature	NULL
B	NULL
cell	NULL
line	NULL
WEHI	NULL
231	NULL
(	NULL
B	NULL
)	NULL
and	NULL
human	NULL
tonsillar	NULL
B	NULL
cells	NULL
(	NULL
C	NULL
)	NULL
were	NULL
stimulated	NULL
for	NULL
15	NULL
min	NULL
as	NULL
indicated	NULL
.	NULL

SAPK	NULL
activities	NULL
were	NULL
determined	NULL
in	NULL
immune	NULL
complex	NULL
assays	NULL
with	NULL
GST-c-Jun	NULL
as	NULL
substrate	NULL
,	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
methods	NULL
.	NULL

A	NULL
PhosphorImager	NULL
was	NULL
used	NULL
to	NULL
calculate	NULL
fold	NULL
induction	NULL
.	NULL

h	NULL
CD40	NULL
,	NULL
human	NULL
CD40	NULL
;	NULL
m	NULL
CD40	NULL
,	NULL
mouse	NULL
CD40	NULL
.	NULL

(	NULL
D	NULL
)	NULL
Before	NULL
tonsillar	NULL
B	NULL
cells	NULL
were	NULL
isolated	NULL
,	NULL
the	NULL
whole	NULL
tonsillar	NULL
cell	NULL
population	NULL
was	NULL
either	NULL
pre-treated	NULL
with	NULL
PMA	NULL
(	NULL
P	NULL
,	NULL
10	NULL
ng/ml	NULL
)	NULL
or	NULL
kept	NULL
in	NULL
medium	NULL
(	NULL
med	NULL
.	NULL
)	NULL

for	NULL
12	NULL
h	NULL
at	NULL
37°C	NULL
.	NULL

Thereafter	NULL
,	NULL
the	NULL
B	NULL
cell	NULL
population	NULL
was	NULL
enriched	NULL
as	NULL
described	NULL
,	NULL
stimulated	NULL
as	NULL
indicated	NULL
and	NULL
tested	NULL
for	NULL
SAPK	NULL
activity	NULL
as	NULL
described	NULL
in	NULL
Figure	NULL
1A	NULL
.	NULL

The	NULL
figure	NULL
shows	NULL
one	NULL
of	NULL
four	NULL
representative	NULL
experiments	NULL
.	NULL

phosphorylation	NULL
of	NULL
MBP	NULL
in	NULL
an	NULL
immune	NULL
complex	NULL
kinase	NULL
assay	NULL
(	NULL
Figure	NULL
4A	NULL
)	NULL
.	NULL

The	NULL
lack	NULL
of	NULL
CD4O0-dependent	NULL
ERK	NULL
1	NULL
and	NULL
ERK2	NULL
activation	NULL
was	NULL
not	NULL
due	NULL
to	NULL
the	NULL
absence	NULL
of	NULL
these	NULL
enzymes	NULL
from	NULL
Daudi	NULL
cells	NULL
,	NULL
since	NULL
activation	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
(	NULL
PKC	NULL
)	NULL
by	NULL
PMA	NULL
and	NULL
the	NULL
calcium	NULL
ionophore	NULL
ionomycin	NULL
did	NULL
activate	NULL
both	NULL
ERK1	NULL
and	NULL
ERK2	NULL
.	NULL

Kinetic	NULL
analyses	NULL
also	NULL
revealed	NULL
that	NULL
ERK2	NULL
was	NULL
not	NULL
activated	NULL
at	NULL
earlier	NULL
or	NULL
later	NULL
time	NULL
points	NULL
,	NULL
up	NULL
to	NULL
90	NULL
min	NULL
after	NULL
CD40	NULL
ligation	NULL
(	NULL
Figure	NULL
4B	NULL
)	NULL
.	NULL

ERK1	NULL
activity	NULL
paralleled	NULL
ERK2	NULL
activity	NULL
in	NULL
those	NULL
cells	NULL
but	NULL
was	NULL
not	NULL
as	NULL
strong	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
no	NULL
significant	NULL
change	NULL
in	NULL
the	NULL
activity	NULL
of	NULL
ERK1	NULL
and	NULL
ERK2	NULL
was	NULL
detected	NULL
in	NULL
the	NULL
murine	NULL
M12/	NULL
CD40	NULL
and	NULL
WEHI	NULL
231	NULL
cell	NULL
lines	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

To	NULL
test	NULL
whether	NULL
CD40	NULL
signaling	NULL
might	NULL
activate	NULL
ERK	NULL
1	NULL
and	NULL
ERK2	NULL
at	NULL
even	NULL
later	NULL
time	NULL
points	NULL
,	NULL
we	NULL
used	NULL
a	NULL
transient	NULL
expression	NULL
assay	NULL
based	NULL
on	NULL
a	NULL
reporter	NULL
plasmid	NULL
,	NULL
5X	NULL
SRE-FOS-CAT/wt	NULL
,	NULL
which	NULL
contains	NULL
five	NULL
copies	NULL
of	NULL
the	NULL
serum	NULL
response	NULL
element	NULL
(	NULL
SRE	NULL
)	NULL
(	NULL
Lee	NULL
and	NULL
Gilman	NULL
,	NULL
1994	NULL
)	NULL
placed	NULL
adjacent	NULL
to	NULL
a	NULL
basic	NULL
c-fos	NULL
promoter	NULL
and	NULL
linked	NULL
to	NULL
CAT	NULL
(	NULL
chloramphenicol	NULL
acetyltransferase	NULL
)	NULL
.	NULL

The	NULL
SREs	NULL
from	NULL
the	NULL
c-fos	NULL
promoter	NULL
bind	NULL
the	NULL
transcription	NULL
factor	NULL
p62	NULL
``	NULL
(	NULL
in	NULL
a	NULL
ternary	NULL
complex	NULL
with	NULL
SRE	NULL
)	NULL
,	NULL
which	NULL
,	NULL
on	NULL
phosphorylation	NULL
by	NULL
ERK	NULL
!	NULL

and	NULL
ERK2	NULL
,	NULL
can	NULL
initiate	NULL
transcription	NULL
of	NULL
the	NULL
reporter	NULL
gene	NULL
(	NULL
Gille	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
;	NULL
Marais	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
.	NULL

Daudi	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
relevant	NULL
reporter	NULL
constructs	NULL
and	NULL
stimulated	NULL
with	NULL
either	NULL
anti-CD40	NULL
monoclonal	NULL
antibody	NULL
(	NULL
mAb	NULL
)	NULL
or	NULL
a	NULL
combination	NULL
of	NULL
PMA	NULL
and	NULL
ionomycin	NULL
during	NULL
the	NULL
last	NULL
16	NULL
h	NULL
of	NULL
the	NULL
transfection	NULL
assay	NULL
.	NULL

Owing	NULL
to	NULL
the	NULL
high	NULL
stability	NULL
of	NULL
the	NULL
CAT	NULL
enzyme	NULL
,	NULL
this	NULL
assay	NULL
should	NULL
pick	NULL
up	NULL
and	NULL
integrate	NULL
any	NULL
change	NULL
in	NULL
ERK1	NULL
and	NULL
ERK2	NULL
activity	NULL
during	NULL
the	NULL
whole	NULL
period	NULL
of	NULL
stimulation	NULL
.	NULL

While	NULL
PMA	NULL
in	NULL
combination	NULL
with	NULL
ionomycin	NULL
strongly	NULL
induced	NULL
SRE-dependent	NULL
gene	NULL
expression	NULL
,	NULL
cross-linking	NULL
CD40	NULL
induced	NULL
little	NULL
or	NULL
no	NULL
expression	NULL
(	NULL
Figure	NULL
5A	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
inability	NULL
of	NULL
the	NULL
CD40	NULL
signal	NULL
to	NULL
induce	NULL
TPA-response	NULL
element	NULL
(	NULL
TRE	NULL
)	NULL
-dependent	NULL
gene	NULL
expression	NULL
is	NULL
most	NULL
likely	NULL
due	NULL
to	NULL
the	NULL
lack	NULL
of	NULL
Fos	NULL
and/or	NULL
to	NULL
the	NULL
fact	NULL
that	NULL
phosphorylation	NULL
of	NULL
Jun	NULL
by	NULL
p46	NULL
SAPK	NULL
alone	NULL
is	NULL
insufficient	NULL
to	NULL
activate	NULL
the	NULL
TRE	NULL
.	NULL

Again	NULL
,	NULL
transfection	NULL
experiments	NULL
with	NULL
M12/CD40	NULL
cells	NULL
yielded	NULL
essentially	NULL
the	NULL
same	NULL
results	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Further	NULL
support	NULL
for	NULL
the	NULL
notion	NULL
that	NULL
CD40	NULL
signaling	NULL
activates	NULL
SAPK	NULL
more	NULL
efficiently	NULL
than	NULL
ERK1	NULL
and	NULL
ERK2	NULL
came	NULL
from	NULL
the	NULL
analyses	NULL
of	NULL
endogenous	NULL
mRNA	NULL
expression	NULL
.	NULL

While	NULL
PMA	NULL
and	NULL
ionomycin	NULL
increased	NULL
both	NULL
c-jun	NULL
and	NULL
c-fos	NULL
mRNA	NULL
levels	NULL
in	NULL
Daudi	NULL
cells	NULL
within	NULL
1	NULL
h	NULL
after	NULL
stimulation	NULL
,	NULL
CD40	NULL
stimulation	NULL
augmented	NULL
only	NULL
c-jun	NULL
mRNA	NULL
expression	NULL
(	NULL
Figure	NULL
5B	NULL
)	NULL
.	NULL

The	NULL
inability	NULL
of	NULL
CD40	NULL
ligation	NULL
to	NULL
activate	NULL
increases	NULL
in	NULL
c-fos	NULL
mRNA	NULL
is	NULL
consistent	NULL
with	NULL
the	NULL
inability	NULL
of	NULL
CD40	NULL
ligation	NULL
to	NULL
activate	NULL
MAPK	NULL
since	NULL
,	NULL
if	NULL
CD40	NULL
ligation	NULL
could	NULL
stimulate	NULL
ERK	NULL
1	NULL
and	NULL
ERK2	NULL
activity	NULL
,	NULL
the	NULL
SRE	NULL
in	NULL
the	NULL
c-fos	NULL
promoter	NULL
should	NULL
also	NULL
be	NULL
activated	NULL
.	NULL

Even	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
cycloheximide	NULL
,	NULL
which	NULL
superinduces	NULL
the	NULL
expression	NULL
of	NULL
early	NULL
response	NULL
genes	NULL
,	NULL
no	NULL
c-fos	NULL
mRNA	NULL
could	NULL
be	NULL
detected	NULL
after	NULL
signaling	NULL
through	NULL
CD40	NULL
.	NULL

Together	NULL
,	NULL
these	NULL
data	NULL
indicate	NULL
that	NULL
cross-linking	NULL
CD40	NULL
activates	NULL
SAPK	NULL
but	NULL
not	NULL
MAPK	NULL
in	NULL
the	NULL
B	NULL
cell	NULL
lines	NULL
examined	NULL
.	NULL

CD40-induced	NULL
SAPK	NULL
activation	NULL
is	NULL
not	NULL
blocked	NULL
by	NULL
pre-treating	NULL
B	NULL
cells	NULL
with	NULL
high	NULL
doses	NULL
of	NULL
phorbol	NULL
ester	NULL
or	NULL
cyclosporin	NULL
A	NULL
The	NULL
data	NULL
thus	NULL
far	NULL
suggested	NULL
that	NULL
PKC	NULL
was	NULL
probably	NULL
not	NULL
involved	NULL
in	NULL
the	NULL
CD4O0-dependent	NULL
SAPK	NULL
activation	NULL
,	NULL
since	NULL
95	NULL
1.Berberich	NULL
et	NULL
al	NULL
.	NULL

Fig	NULL
.	NULL

4	NULL
.	NULL

Cross-linking	NULL
CD40	NULL
preferentially	NULL
activates	NULL
SAPK	NULL
compared	NULL
with	NULL
ERK1	NULL
and	NULL
ERK2	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Daudi	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
anti-CD40	NULL
mAb	NULL
(	NULL
0.5	NULL
ug/m	NULL
!	NULL

1	NULL
)	NULL
or	NULL
a	NULL
combination	NULL
of	NULL
PMA	NULL
(	NULL
P	NULL
,	NULL
50	NULL
ng/m	NULL
!	NULL
)	NULL

and	NULL
ionomycin	NULL
(	NULL
I	NULL
,	NULL
0.25	NULL
ug/ml	NULL
!	NULL
)	NULL

for	NULL
the	NULL
times	NULL
indicated	NULL
.	NULL

SAPK	NULL
and/or	NULL
ERK	NULL
1	NULL
and	NULL
ERK2	NULL
were	NULL
precipitated	NULL
and	NULL
tested	NULL
for	NULL
their	NULL
activities	NULL
in	NULL
immune	NULL
complex	NULL
kinase	NULL
assays	NULL
using	NULL
GST-c-Jun	NULL
and/or	NULL
MBP	NULL
as	NULL
substrates	NULL
in	NULL
various	NULL
combinations	NULL
.	NULL

In	NULL
the	NULL
immune	NULL
complex	NULL
kinase	NULL
assays	NULL
shown	NULL
in	NULL
the	NULL
right	NULL
panel	NULL
,	NULL
the	NULL
various	NULL
combinations	NULL
of	NULL
kinases	NULL
and	NULL
substrates	NULL
were	NULL
tested	NULL
to	NULL
ensure	NULL
kinase/substrate	NULL
specificity	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Daudi	NULL
cells	NULL
were	NULL
treated	NULL
as	NULL
indicated	NULL
.	NULL

SAPK	NULL
and	NULL
ERK	NULL
?	NULL

activities	NULL
were	NULL
determined	NULL
in	NULL
in-gel	NULL
kinase	NULL
assays	NULL
with	NULL
GST-c-Jun	NULL
and	NULL
MBP	NULL
,	NULL
respectively	NULL
.	NULL

In	NULL
the	NULL
upper	NULL
panel	NULL
,	NULL
an	NULL
asterisk	NULL
marks	NULL
the	NULL
lane	NULL
where	NULL
a	NULL
polyclonal	NULL
antiserum	NULL
directed	NULL
against	NULL
a	NULL
GST-SAPK	NULL
fusion	NULL
protein	NULL
(	NULL
Kyriakis	NULL
er	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
was	NULL
used	NULL
for	NULL
comparison	NULL
.	NULL

In	NULL
all	NULL
the	NULL
other	NULL
lanes	NULL
of	NULL
this	NULL
panel	NULL
,	NULL
the	NULL
JNK	NULL
1	NULL
(	NULL
C-17	NULL
)	NULL
antiserum	NULL
directed	NULL
against	NULL
a	NULL
C-terminal	NULL
peptide	NULL
of	NULL
SAPK	NULL
was	NULL
used	NULL
.	NULL

In	NULL
the	NULL
lower	NULL
panel	NULL
,	NULL
an	NULL
asterisk	NULL
marks	NULL
the	NULL
lane	NULL
where	NULL
an	NULL
antiserum	NULL
against	NULL
ERK	NULL
!	NULL

was	NULL
used	NULL
for	NULL
precipitation	NULL
.	NULL

Anti-rac2	NULL
antiserum	NULL
was	NULL
used	NULL
to	NULL
control	NULL
for	NULL
specificity	NULL
(	NULL
cont	NULL
.	NULL

Ab	NULL
)	NULL
.	NULL

Molecular	NULL
weight	NULL
standards	NULL
are	NULL
indicated	NULL
in	NULL
kDa	NULL
.	NULL

induction	NULL
of	NULL
PKC	NULL
normally	NULL
activates	NULL
ERK1	NULL
and	NULL
ERK2	NULL
via	NULL
Raf-1	NULL
(	NULL
Kolch	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
.	NULL

To	NULL
test	NULL
whether	NULL
PKC	NULL
is	NULL
required	NULL
for	NULL
CD40	NULL
activation	NULL
of	NULL
SAPK	NULL
,	NULL
we	NULL
pre-treated	NULL
M12/CD40	NULL
cells	NULL
with	NULL
high	NULL
doses	NULL
of	NULL
PMA	NULL
(	NULL
0.3	NULL
ug/ml	NULL
)	NULL
for	NULL
16	NULL
h	NULL
to	NULL
deplete	NULL
PKC	NULL
levels	NULL
.	NULL

PMA	NULL
pre-treatment	NULL
totally	NULL
abrogated	NULL
-	NULL
PKC-dependent	NULL
-	NULL
PMA/ionomycin-induced	NULL
SAPK	NULL
and	NULL
ERK2	NULL
activity	NULL
at	NULL
10	NULL
and	NULL
60	NULL
min	NULL
after	NULL
stimulation	NULL
but	NULL
left	NULL
CD4O0-stimulated	NULL
SAPK	NULL
activity	NULL
untouched	NULL
(	NULL
Figure	NULL
6A	NULL
)	NULL
.	NULL

The	NULL
same	NULL
result	NULL
was	NULL
obtained	NULL
when	NULL
PKC-depleted	NULL
Daudi	NULL
cells	NULL
were	NULL
used	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
PKC	NULL
96	NULL
apparently	NULL
is	NULL
not	NULL
required	NULL
for	NULL
the	NULL
CD40	NULL
signaling	NULL
pathway	NULL
leading	NULL
to	NULL
SAPK	NULL
activation	NULL
.	NULL

Because	NULL
SAPK	NULL
activated	NULL
by	NULL
ligation	NULL
of	NULL
both	NULL
CD3	NULL
and	NULL
CD28	NULL
receptors	NULL
on	NULL
T	NULL
cells	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
sensitive	NULL
to	NULL
cyclosporin	NULL
A	NULL
(	NULL
CsA	NULL
)	NULL
,	NULL
we	NULL
examined	NULL
whether	NULL
CD40-induced	NULL
SAPK	NULL
in	NULL
Daudi	NULL
cells	NULL
was	NULL
influenced	NULL
by	NULL
CsA	NULL
.	NULL

While	NULL
CsA	NULL
strongly	NULL
suppressed	NULL
the	NULL
induction	NULL
of	NULL
SAPK	NULL
by	NULL
PMA	NULL
and	NULL
ionomycin	NULL
,	NULL
it	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
CD40-induced	NULL
SAPK	NULL
15	NULL
min	NULL
(	NULL
Figure	NULL
6B	NULL
)	NULL
or	NULL
30	NULL
min	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
post-stimulation	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
CD40-SAPK	NULL
pathway	NULL
was	NULL
also	NULL
insensitive	NULL
to	NULL
CsA	NULL
in	NULL
murine	NULL
M12/CD40	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Cross-linking	NULL
CD40	NULL
changes	NULL
the	NULL
electrophoretic	NULL
mobility	NULL
of	NULL
ATF2	NULL
but	NULL
not	NULL
of	NULL
Raf-1	NULL
It	NULL
has	NULL
been	NULL
reported	NULL
that	NULL
ATF2	NULL
is	NULL
phosphorylated	NULL
by	NULL
activated	NULL
SAPK	NULL
and	NULL
that	NULL
phosphorylation	NULL
of	NULL
ATF2	NULL
correlates	NULL
with	NULL
a	NULL
shift	NULL
in	NULL
ATF2	NULL
mobility	NULL
in	NULL
SDS-PAGE	NULL
(	NULL
Gupta	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

Consistent	NULL
with	NULL
those	NULL
results	NULL
,	NULL
we	NULL
found	NULL
that	NULL
the	NULL
electrophoretic	NULL
mobility	NULL
of	NULL
ATF2	NULL
in	NULL
Daudi	NULL
cells	NULL
was	NULL
also	NULL
altered	NULL
after	NULL
cross-linking	NULL
CD40	NULL
,	NULL
and	NULL
this	NULL
change	NULL
in	NULL
mobility	NULL
paralleled	NULL
the	NULL
activation	NULL
of	NULL
SAPK	NULL
(	NULL
Figure	NULL
7a	NULL
and	NULL
b	NULL
)	NULL
.	NULL

We	NULL
also	NULL
performed	NULL
an	NULL
analogous	NULL
experiment	NULL
for	NULL
Raf-1	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
ATF2	NULL
,	NULL
Raf-1	NULL
mobility	NULL
was	NULL
influenced	NULL
not	NULL
by	NULL
CD40	NULL
signaling	NULL
but	NULL
by	NULL
PMA	NULL
and	NULL
ionomycin	NULL
(	NULL
Figure	NULL
7¢	NULL
)	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
CD4O0-induced	NULL
SAPK	NULL
may	NULL
phosphorylate	NULL
and	NULL
thereby	NULL
activate	NULL
ATF2	NULL
,	NULL
implying	NULL
that	NULL
this	NULL
transcription	NULL
factor	NULL
may	NULL
function	NULL
as	NULL
a	NULL
downstream	NULL
mediator	NULL
of	NULL
CD40	NULL
signaling	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
these	NULL
data	NULL
indicate	NULL
that	NULL
the	NULL
CD40	NULL
pathway	NULL
does	NULL
not	NULL
involve	NULL
Raf-1	NULL
activation	NULL
.	NULL

Discussion	NULL
In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
evaluated	NULL
whether	NULL
cross-linking	NULL
CD40	NULL
on	NULL
B	NULL
cell	NULL
lines	NULL
and	NULL
human	NULL
tonsillar	NULL
B	NULL
cells	NULL
activates	NULL
SAPKs	NULL
and	NULL
MAPKs	NULL
(	NULL
ERK	NULL
and	NULL
ERK2	NULL
)	NULL
.	NULL

Our	NULL
results	NULL
clearly	NULL
demonstrate	NULL
that	NULL
signaling	NULL
through	NULL
CD40	NULL
can	NULL
up-regulate	NULL
the	NULL
activity	NULL
of	NULL
SAPK	NULL
while	NULL
affecting	NULL
ERK1	NULL
and	NULL
ERK2	NULL
activity	NULL
only	NULL
marginally	NULL
,	NULL
if	NULL
at	NULL
all	NULL
.	NULL

Several	NULL
lines	NULL
of	NULL
evidence	NULL
indicate	NULL
that	NULL
ERK	NULL
1	NULL
and	NULL
ERK2	NULL
are	NULL
not	NULL
significantly	NULL
activated	NULL
by	NULL
CD40	NULL
:	NULL
(	NULL
i	NULL
)	NULL
no	NULL
significant	NULL
phosphorylation	NULL
of	NULL
MBP	NULL
was	NULL
detected	NULL
with	NULL
anti-ERK	NULL
1	NULL
and	NULL
ERK2	NULL
precipitates	NULL
in	NULL
in	NULL
vitro	NULL
kinase	NULL
assays	NULL
after	NULL
CD40	NULL
cross-linking	NULL
for	NULL
various	NULL
lengths	NULL
of	NULL
time	NULL
;	NULL
(	NULL
ii	NULL
)	NULL
no	NULL
significant	NULL
SRE-dependent	NULL
reporter	NULL
gene	NULL
expression	NULL
was	NULL
detected	NULL
after	NULL
CD40	NULL
ligation	NULL
,	NULL
which	NULL
should	NULL
pick	NULL
up	NULL
any	NULL
ERK1	NULL
and	NULL
ERK2	NULL
activity	NULL
via	NULL
an	NULL
activated	NULL
p62	NULL
``	NULL
C	NULL
``	NULL
(	NULL
Gille	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
;	NULL
Marais	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
;	NULL
and	NULL
(	NULL
iii	NULL
)	NULL
no	NULL
endogenous	NULL
c-fos	NULL
mRNA	NULL
was	NULL
expressed	NULL
after	NULL
CD40	NULL
signaling	NULL
.	NULL

However	NULL
,	NULL
the	NULL
CD4O0-induced	NULL
SAPK	NULL
response	NULL
could	NULL
be	NULL
quite	NULL
strong	NULL
,	NULL
with	NULL
15-	NULL
to	NULL
25-fold	NULL
increases	NULL
in	NULL
activity	NULL
in	NULL
Daudi	NULL
cells	NULL
.	NULL

The	NULL
activity	NULL
peaked	NULL
at	NULL
~10-15	NULL
min	NULL
after	NULL
the	NULL
engagement	NULL
of	NULL
CD40	NULL
and	NULL
declined	NULL
thereafter	NULL
,	NULL
but	NULL
persisted	NULL
for	NULL
several	NULL
hours	NULL
.	NULL

Although	NULL
p46	NULL
SAPK	NULL
is	NULL
preferentially	NULL
activated	NULL
compared	NULL
with	NULL
p54	NULL
SAPK	NULL
and	NULL
the	NULL
ERK1/2	NULL
kinases	NULL
in	NULL
the	NULL
B	NULL
cells	NULL
we	NULL
have	NULL
studied	NULL
,	NULL
it	NULL
is	NULL
possible	NULL
that	NULL
in	NULL
other	NULL
cell	NULL
types	NULL
or	NULL
stages	NULL
ligating	NULL
CD40	NULL
may	NULL
produce	NULL
a	NULL
different	NULL
pattern	NULL
of	NULL
p46/p54	NULL
SAPK	NULL
and/or	NULL
ERK1/2	NULL
activation	NULL
.	NULL

For	NULL
example	NULL
,	NULL
Rafiee	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
recently	NULL
found	NULL
that	NULL
TNF-	NULL
@	NULL
,	NULL
which	NULL
preferentially	NULL
induces	NULL
SAPK	NULL
activation	NULL
in	NULL
a	NULL
number	NULL
of	NULL
cell	NULL
types	NULL
(	NULL
Kyriakis	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
,	NULL
did	NULL
activate	NULL
ERK	NULL
in	NULL
human	NULL
neutrophils	NULL
.	NULL

SAPK	NULL
apparently	NULL
may	NULL
be	NULL
activated	NULL
via	NULL
either	NULL
Ras-	NULL
P90	NULL
oo0e	NULL
eee	NULL
#	NULL
#	NULL
Cross-linking	NULL
CD40	NULL
activates	NULL
SAPK	NULL
Fig	NULL
.	NULL

5	NULL
.	NULL

Gene	NULL
expression	NULL
after	NULL
cross-linking	NULL
CD40	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Daudi	NULL
cells	NULL
were	NULL
transiently	NULL
transfected	NULL
with	NULL
CAT	NULL
reporter	NULL
constructs	NULL
[	NULL
5X	NULL
SRE-FOS-CAT/wt	NULL
(	NULL
a	NULL
)	NULL
,	NULL
5x	NULL
SRE-FOS-CAT/mp12	NULL
(	NULL
b	NULL
)	NULL
,	NULL
5	NULL
%	NULL
TREcol	NULL
(	NULL
c	NULL
)	NULL
or	NULL
pBL2	NULL
7+	NULL
(	NULL
contains	NULL
NF-xB	NULL
binding	NULL
sites	NULL
;	NULL
d	NULL
)	NULL
]	NULL
.	NULL

One	NULL
day	NULL
after	NULL
transfection	NULL
,	NULL
cells	NULL
were	NULL
split	NULL
and	NULL
stimulated	NULL
for	NULL
16	NULL
h	NULL
with	NULL
the	NULL
stimulus	NULL
indicated	NULL
[	NULL
anti-CD40	NULL
mAb	NULL
,	NULL
0.5	NULL
ug/ml	NULL
;	NULL
PMA	NULL
(	NULL
P	NULL
)	NULL
,	NULL
50	NULL
ng/ml	NULL
;	NULL
and	NULL
ionomycin	NULL
(	NULL
I	NULL
)	NULL
0.25	NULL
ug/ml	NULL
]	NULL
.	NULL

CAT	NULL
assays	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
methods	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Daudi	NULL
cells	NULL
were	NULL
treated	NULL
as	NULL
indicated	NULL
[	NULL
mAb	NULL
,	NULL
0.5	NULL
ug/ml	NULL
;	NULL
PMA	NULL
(	NULL
P	NULL
)	NULL
,	NULL
50	NULL
ng/ml	NULL
;	NULL
ionomycin	NULL
(	NULL
D	NULL
)	NULL
,	NULL
0.25	NULL
ug/ml	NULL
;	NULL
and	NULL
cycloheximide	NULL
(	NULL
Chx	NULL
)	NULL
,	NULL
20	NULL
ug/ml	NULL
]	NULL
.	NULL

Total	NULL
RNA	NULL
was	NULL
isolated	NULL
and	NULL
tested	NULL
for	NULL
c-jun	NULL
and	NULL
c-fos	NULL
mRNA	NULL
levels	NULL
.	NULL

Equal	NULL
loading	NULL
was	NULL
confirmed	NULL
by	NULL
rehybridizing	NULL
the	NULL
membranes	NULL
with	NULL
a	NULL
B-actin	NULL
probe	NULL
.	NULL

<	NULL
e	NULL
age	NULL
Fig	NULL
.	NULL

6	NULL
.	NULL

CD40-dependent	NULL
activation	NULL
of	NULL
SAPK	NULL
is	NULL
not	NULL
blocked	NULL
by	NULL
pre-treating	NULL
M12/CD40	NULL
cells	NULL
with	NULL
high	NULL
doses	NULL
of	NULL
PMA	NULL
or	NULL
by	NULL
the	NULL
inhibitor	NULL
cyclosporin	NULL
A	NULL
(	NULL
CsA	NULL
)	NULL
.	NULL

(	NULL
A	NULL
)	NULL
M12/CD40	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
medium	NULL
alone	NULL
(	NULL
a	NULL
)	NULL
or	NULL
with	NULL
PMA	NULL
(	NULL
300	NULL
ng/ml	NULL
)	NULL
(	NULL
b	NULL
)	NULL
for	NULL
16	NULL
h.	NULL
Cells	NULL
were	NULL
then	NULL
stimulated	NULL
as	NULL
indicated	NULL
[	NULL
anti-CD40	NULL
,	NULL
0.5	NULL
ug/ml	NULL
;	NULL
PMA	NULL
(	NULL
P	NULL
)	NULL
,	NULL
50	NULL
ng/ml	NULL
;	NULL
and	NULL
ionomycin	NULL
(	NULL
1	NULL
)	NULL
0.25	NULL
ug/ml	NULL
]	NULL
.	NULL

SAPK	NULL
and	NULL
ERK2	NULL
were	NULL
precipitated	NULL
and	NULL
tested	NULL
for	NULL
their	NULL
activity	NULL
in	NULL
immune	NULL
complex	NULL
kinase	NULL
assays	NULL
including	NULL
GST~-c-Jun	NULL
and	NULL
MBP	NULL
as	NULL
substrates	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Daudi	NULL
cells	NULL
were	NULL
either	NULL
pre-treated	NULL
with	NULL
CsA	NULL
for	NULL
1	NULL
h	NULL
as	NULL
indicated	NULL
or	NULL
left	NULL
untreated	NULL
prior	NULL
to	NULL
stimulation	NULL
[	NULL
concentrations	NULL
as	NULL
in	NULL
(	NULL
A	NULL
)	NULL
]	NULL
.	NULL

Lysis	NULL
and	NULL
testing	NULL
for	NULL
SAPK	NULL
activity	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
methods	NULL
.	NULL

dependent	NULL
or	NULL
Ras-independent	NULL
pathways	NULL
(	NULL
Bird	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
Minden	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994a	NULL
)	NULL
.	NULL

We	NULL
have	NULL
no	NULL
direct	NULL
data	NULL
supporting	NULL
one	NULL
pathway	NULL
or	NULL
the	NULL
other	NULL
,	NULL
but	NULL
two	NULL
findings	NULL
argue	NULL
in	NULL
favor	NULL
of	NULL
the	NULL
Ras-independent	NULL
pathway	NULL
.	NULL

First	NULL
,	NULL
cross-linking	NULL
CD40	NULL
does	NULL
not	NULL
lead	NULL
to	NULL
the	NULL
changes	NULL
in	NULL
Raf-1	NULL
mobility	NULL
(	NULL
Figure	NULL
7¢	NULL
)	NULL
that	NULL
one	NULL
might	NULL
expect	NULL
after	NULL
activation	NULL
.	NULL

Second	NULL
,	NULL
the	NULL
related	NULL
TNF-a	NULL
receptors	NULL
(	NULL
TNF-oRs	NULL
)	NULL
and	NULL
CD40	NULL
share	NULL
a	NULL
number	NULL
of	NULL
highly	NULL
conserved	NULL
features	NULL
:	NULL
all	NULL
three	NULL
surface	NULL
molecules	NULL
belong	NULL
to	NULL
the	NULL
same	NULL
protein	NULL
family	NULL
(	NULL
Smith	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
;	NULL
CD40	NULL
and	NULL
TNF-ouR	NULL
p75	NULL
bind	NULL
highly	NULL
homologous	NULL
proteins	NULL
with	NULL
their	NULL
cytoplasmic	NULL
tail-TRAF2	NULL
for	NULL
the	NULL
TNF-	NULL
«	NULL
R	NULL
p75	NULL
(	NULL
Rothe	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
and	NULL
CRAFl	NULL
for	NULL
CD40	NULL
(	NULL
Hu	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
Cheng	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
;	NULL
Mosialos	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
;	NULL
both	NULL
CD40	NULL
and	NULL
TNF-aR	NULL
p55	NULL
activate	NULL
NF-KB	NULL
(	NULL
Kruppa	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
;	NULL
Berberich	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
;	NULL
and	NULL
CD40	NULL
and	NULL
the	NULL
TNF-aR	NULL
(	NULL
s	NULL
)	NULL
,	NULL
p55	NULL
and/or	NULL
p75	NULL
,	NULL
both	NULL
target	NULL
SAPK	NULL
(	NULL
Figures	NULL
1-4	NULL
;	NULL
see	NULL
also	NULL
Kyriakis	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
Minden	NULL
et	NULL
al	NULL
.	NULL

,	NULL
19942	NULL
)	NULL
,	NULL
with	NULL
the	NULL
TNF-auR	NULL
(	NULL
s	NULL
)	NULL
acting	NULL
in	NULL
a	NULL
Ras-independent	NULL
way	NULL
.	NULL

Thus	NULL
,	NULL
it	NULL
is	NULL
likely	NULL
that	NULL
CD40	NULL
may	NULL
signal	NULL
in	NULL
a	NULL
similar	NULL
manner	NULL
.	NULL

Cross-linking	NULL
CD40	NULL
leads	NULL
to	NULL
c-jun	NULL
mRNA	NULL
expression	NULL
in	NULL
Daudi	NULL
cells	NULL
(	NULL
Figure	NULL
5B	NULL
)	NULL
.	NULL

There	NULL
was	NULL
a	NULL
good	NULL
correlation	NULL
between	NULL
the	NULL
strength	NULL
of	NULL
SAPK	NULL
activity	NULL
and	NULL
the	NULL
amount	NULL
of	NULL
c-jun	NULL
mRNA	NULL
expressed	NULL
.	NULL

Nevertheless	NULL
,	NULL
it	NULL
is	NULL
not	NULL
yet	NULL
clear	NULL
whether	NULL
the	NULL
transcription	NULL
factors	NULL
known	NULL
to	NULL
be	NULL
effectors	NULL
of	NULL
SAPK	NULL
,	NULL
i.e	NULL
.	NULL

c-Jun	NULL
(	NULL
Hibi	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
and	NULL
ATF2	NULL
(	NULL
Gupta	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
,	NULL
are	NULL
in	NULL
fact	NULL
responsible	NULL
and	NULL
sufficient	NULL
to	NULL
97	NULL
Fig	NULL
.	NULL

7	NULL
.	NULL

Cross-linking	NULL
CD40	NULL
changes	NULL
the	NULL
electrophoretic	NULL
mobility	NULL
of	NULL
ATF2	NULL
but	NULL
not	NULL
of	NULL
Raf-1	NULL
.	NULL

Daudi	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
anti-CD40	NULL
mAb	NULL
(	NULL
0.5	NULL
ug/ml	NULL
)	NULL
or	NULL
a	NULL
combination	NULL
of	NULL
PMA	NULL
(	NULL
P	NULL
,	NULL
50	NULL
ng/ml	NULL
)	NULL
and	NULL
ionomycin	NULL
(	NULL
I	NULL
,	NULL
0.25	NULL
ug/m	NULL
!	NULL
)	NULL

for	NULL
the	NULL
times	NULL
indicated	NULL
.	NULL

Extracts	NULL
were	NULL
then	NULL
immunoprecipitated	NULL
with	NULL
polyclonal	NULL
antisera	NULL
directed	NULL
against	NULL
ATF2	NULL
or	NULL
Raf-1	NULL
.	NULL

Immunoprecipitates	NULL
were	NULL
subjected	NULL
to	NULL
SDS-PAGE	NULL
and	NULL
visualized	NULL
by	NULL
Western	NULL
blotting	NULL
(	NULL
b	NULL
and	NULL
¢	NULL
)	NULL
.	NULL

SAPK	NULL
activity	NULL
of	NULL
the	NULL
cells	NULL
was	NULL
monitored	NULL
by	NULL
means	NULL
of	NULL
an	NULL
immune	NULL
complex	NULL
kinase	NULL
assay	NULL
(	NULL
a	NULL
)	NULL
.	NULL

account	NULL
for	NULL
the	NULL
up-regulation	NULL
of	NULL
the	NULL
c-jun	NULL
promoter	NULL
.	NULL

After	NULL
CD40	NULL
cross-linking	NULL
,	NULL
c-fos	NULL
mRNA	NULL
was	NULL
not	NULL
detectable	NULL
(	NULL
Figure	NULL
5B	NULL
)	NULL
and	NULL
a	NULL
reporter	NULL
gene	NULL
dependent	NULL
on	NULL
the	NULL
classical	NULL
AP-1	NULL
(	NULL
Jun/Fos	NULL
)	NULL
heterodimer	NULL
was	NULL
not	NULL
expressed	NULL
significantly	NULL
(	NULL
Figure	NULL
5A	NULL
;	NULL
see	NULL
also	NULL
Berberich	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
it	NULL
seems	NULL
unlikely	NULL
that	NULL
AP-1	NULL
,	NULL
a	NULL
potent	NULL
regulator	NULL
of	NULL
the	NULL
c-jun	NULL
promoter	NULL
(	NULL
Angel	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
,	NULL
contributes	NULL
to	NULL
the	NULL
increase	NULL
in	NULL
c-jun	NULL
mRNA	NULL
found	NULL
after	NULL
CD40	NULL
cross-linking	NULL
.	NULL

Jun2/	NULL
TRE	NULL
is	NULL
another	NULL
regulatory	NULL
site	NULL
in	NULL
the	NULL
5	NULL
region	NULL
of	NULL
the	NULL
c-jun	NULL
gene	NULL
.	NULL

It	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
bind	NULL
ATF2/c-Jun	NULL
hetero-dimers	NULL
(	NULL
van	NULL
Dam	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
and	NULL
to	NULL
exert	NULL
a	NULL
regulatory	NULL
function	NULL
in	NULL
ATF2-dependent	NULL
c-jur	NULL
promoter	NULL
activity	NULL
(	NULL
Livingstone	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
;	NULL
van	NULL
Dam	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

Since	NULL
CD40	NULL
ligation	NULL
induces	NULL
a	NULL
migrating	NULL
shift	NULL
in	NULL
ATF2	NULL
(	NULL
Figure	NULL
7b	NULL
)	NULL
,	NULL
and	NULL
ATF2	NULL
contains	NULL
a	NULL
phosphorylation-dependent	NULL
transcription	NULL
activation	NULL
domain	NULL
(	NULL
Livingstone	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
;	NULL
van	NULL
Dam	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
,	NULL
Jun2/TRE	NULL
seems	NULL
a	NULL
likely	NULL
target	NULL
site	NULL
for	NULL
SAPK-dependent	NULL
c-jun	NULL
up-regulation	NULL
.	NULL

Recently	NULL
,	NULL
Francis	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
found	NULL
some	NULL
increase	NULL
in	NULL
the	NULL
TRE	NULL
(	NULL
AP-1	NULL
site	NULL
)	NULL
binding	NULL
activity	NULL
after	NULL
cross-linking	NULL
CD40	NULL
on	NULL
primary	NULL
murine	NULL
B	NULL
cells	NULL
.	NULL

Thus	NULL
,	NULL
as	NULL
yet	NULL
uncharacterized	NULL
TRE	NULL
site	NULL
binding	NULL
activity	NULL
may	NULL
influence	NULL
transcripitional	NULL
activity	NULL
of	NULL
the	NULL
c-jun	NULL
gene	NULL
.	NULL

Further	NULL
transcripton	NULL
factors	NULL
could	NULL
also	NULL
be	NULL
involved	NULL
in	NULL
CD4O0-dependent	NULL
c-jun	NULL
expression	NULL
.	NULL

NF-KB	NULL
could	NULL
be	NULL
a	NULL
potential	NULL
candidate	NULL
because	NULL
:	NULL
(	NULL
i	NULL
)	NULL
it	NULL
is	NULL
strongly	NULL
induced	NULL
by	NULL
CD40	NULL
signals	NULL
(	NULL
Berberich	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
;	NULL
(	NULL
ii	NULL
)	NULL
NF-KB	NULL
and	NULL
ATF2	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
interact	NULL
in	NULL
vitro	NULL
(	NULL
Du	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
;	NULL
and	NULL
(	NULL
iii	NULL
)	NULL
DNA	NULL
sequences	NULL
differing	NULL
in	NULL
only	NULL
one	NULL
residue	NULL
from	NULL
an	NULL
NF-xB	NULL
consensus	NULL
site	NULL
are	NULL
located	NULL
in	NULL
the	NULL
c-jun	NULL
promoter	NULL
region	NULL
close	NULL
to	NULL
the	NULL
ATF2	NULL
binding	NULL
site	NULL
(	NULL
D.Morris	NULL
,	NULL
personal	NULL
communication	NULL
)	NULL
.	NULL

Consistent	NULL
with	NULL
data	NULL
published	NULL
by	NULL
Gille	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
,	NULL
c-fos	NULL
mRNA	NULL
expression	NULL
in	NULL
B	NULL
cells	NULL
correlates	NULL
with	NULL
ERK	NULL
98	NULL
activity	NULL
(	NULL
Figure	NULL
5B	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

So	NULL
far	NULL
,	NULL
we	NULL
have	NULL
been	NULL
unable	NULL
to	NULL
definitely	NULL
exclude	NULL
the	NULL
involvement	NULL
of	NULL
SAPK	NULL
and	NULL
thus	NULL
a	NULL
dual	NULL
signal	NULL
requirement	NULL
for	NULL
c-fos	NULL
mRNA	NULL
expression	NULL
due	NULL
to	NULL
the	NULL
lack	NULL
of	NULL
a	NULL
stimulus	NULL
which	NULL
exclusively	NULL
activates	NULL
ERK	NULL
in	NULL
our	NULL
system	NULL
.	NULL

However	NULL
,	NULL
we	NULL
have	NULL
compared	NULL
anti-IgM	NULL
with	NULL
anti-IgM/anti-CD40	NULL
stimulation	NULL
in	NULL
WEHI	NULL
231	NULL
cells	NULL
and	NULL
analyzed	NULL
them	NULL
with	NULL
respect	NULL
to	NULL
SAPK	NULL
and	NULL
ERK	NULL
activation	NULL
and	NULL
c-fos	NULL
mRNA	NULL
expression	NULL
.	NULL

Both	NULL
stimuli	NULL
induced	NULL
identical	NULL
ERK	NULL
activation	NULL
and	NULL
c-fos	NULL
mRNA	NULL
expression	NULL
,	NULL
even	NULL
though	NULL
there	NULL
was	NULL
a	NULL
dramatically	NULL
higher	NULL
SAPK	NULL
activation	NULL
in	NULL
doubly	NULL
stimulated	NULL
cells	NULL
(	NULL
Siebelt	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
at	NULL
least	NULL
the	NULL
level	NULL
of	NULL
SAPK	NULL
activity	NULL
did	NULL
not	NULL
influence	NULL
ERK-dependent	NULL
c-fos	NULL
mRNA	NULL
expression	NULL
.	NULL

The	NULL
ERK	NULL
dependency	NULL
of	NULL
c-fos	NULL
expression	NULL
was	NULL
demonstrated	NULL
by	NULL
stimulating	NULL
the	NULL
cells	NULL
with	NULL
anti-CD40	NULL
alone	NULL
,	NULL
which	NULL
again	NULL
led	NULL
to	NULL
strong	NULL
SAPK	NULL
induction-comparable	NULL
with	NULL
doubly	NULL
stimulated	NULL
cells-but	NULL
neither	NULL
ERK	NULL
activation	NULL
nor	NULL
c-fos	NULL
mRNA	NULL
expression	NULL
(	NULL
Siebelt	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

CD40	NULL
signals	NULL
lead	NULL
to	NULL
changes	NULL
in	NULL
a	NULL
variety	NULL
of	NULL
downstream	NULL
signal	NULL
transducers	NULL
including	NULL
protein	NULL
tyrosine	NULL
kinases	NULL
(	NULL
Faris	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
,	NULL
the	NULL
PI-3	NULL
kinase	NULL
(	NULL
Ren	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
,	NULL
the	NULL
SAPK	NULL
(	NULL
Figures	NULL
1-4	NULL
)	NULL
and	NULL
the	NULL
transcription	NULL
factors	NULL
NF-	NULL
«	NULL
B	NULL
(	NULL
Berberich	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
Francis	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
and	NULL
NF-AT	NULL
;	NULL
for	NULL
the	NULL
latter	NULL
a	NULL
co-stimulatory	NULL
signal	NULL
may	NULL
be	NULL
necessary	NULL
(	NULL
Choi	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
Francis	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

Intriguingly	NULL
,	NULL
in	NULL
Daudi	NULL
cells	NULL
,	NULL
the	NULL
onsets	NULL
of	NULL
activation	NULL
of	NULL
NF-KB	NULL
and	NULL
SAPK	NULL
after	NULL
CD40	NULL
cross-linking	NULL
are	NULL
basically	NULL
parallel	NULL
(	NULL
Figure	NULL
2C	NULL
)	NULL
.	NULL

On	NULL
the	NULL
basis	NULL
of	NULL
this	NULL
coordinated	NULL
action	NULL
,	NULL
it	NULL
is	NULL
possible	NULL
that	NULL
the	NULL
SAPK	NULL
lies	NULL
upstream	NULL
on	NULL
a	NULL
pathway	NULL
leading	NULL
to	NULL
phosphorylation	NULL
of	NULL
IxB	NULL
(	NULL
-a	NULL
and/or	NULL
-B	NULL
)	NULL
and	NULL
subsequently	NULL
to	NULL
activation	NULL
of	NULL
NF-KB	NULL
,	NULL
or	NULL
that	NULL
SAPK	NULL
per	NULL
se	NULL
is	NULL
the	NULL
kinase	NULL
that	NULL
phosphorylates	NULL
IxB	NULL
(	NULL
s	NULL
)	NULL
.	NULL

However	NULL
,	NULL
we	NULL
have	NULL
not	NULL
detected	NULL
phosphorylation	NULL
of	NULL
IKB-	NULL
@	NULL
with	NULL
activated	NULL
SAPK	NULL
(	NULL
unpub-lished	NULL
observation	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
pre-treatment	NULL
of	NULL
Daudi	NULL
cells	NULL
with	NULL
the	NULL
anti-oxidant	NULL
pyrrolidine	NULL
dithiocarbamate	NULL
totally	NULL
inhibits	NULL
CD40-induced	NULL
NF-KB	NULL
activation	NULL
(	NULL
Berberich	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
but	NULL
,	NULL
at	NULL
the	NULL
same	NULL
doses	NULL
,	NULL
activates	NULL
the	NULL
SAPK	NULL
by	NULL
itself	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
our	NULL
data	NULL
at	NULL
this	NULL
juncture	NULL
favor	NULL
a	NULL
model	NULL
in	NULL
which	NULL
SAPK	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
are	NULL
located	NULL
on	NULL
parallel	NULL
pathways	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
Daudi	NULL
,	NULL
M12	NULL
and	NULL
WEHI	NULL
231	NULL
cells	NULL
,	NULL
another	NULL
human	NULL
B	NULL
cell	NULL
line	NULL
,	NULL
B104	NULL
(	NULL
Ishigami	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
,	NULL
showed	NULL
no	NULL
increase	NULL
in	NULL
SAPK	NULL
activity	NULL
after	NULL
CD40	NULL
cross-linking	NULL
,	NULL
even	NULL
though	NULL
SAPK	NULL
was	NULL
present	NULL
and	NULL
activatable	NULL
by	NULL
phorbol	NULL
ester	NULL
and	NULL
ionomycin	NULL
in	NULL
these	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
freshly	NULL
isolated	NULL
human	NULL
tonsillar	NULL
B	NULL
cell	NULL
preparations	NULL
varied	NULL
in	NULL
their	NULL
response	NULL
to	NULL
CD40	NULL
;	NULL
responsiveness	NULL
to	NULL
CD40	NULL
ligation	NULL
may	NULL
depend	NULL
on	NULL
the	NULL
maturation	NULL
or	NULL
activation	NULL
stage	NULL
of	NULL
B	NULL
cells	NULL
,	NULL
i.e	NULL
.	NULL

the	NULL
CD40-SAPK	NULL
linkage	NULL
may	NULL
not	NULL
exist	NULL
(	NULL
physically	NULL
or	NULL
functionally	NULL
)	NULL
at	NULL
every	NULL
B	NULL
cell	NULL
stage	NULL
.	NULL

Pre-activation	NULL
of	NULL
tonsillar	NULL
B	NULL
cells	NULL
with	NULL
PMA	NULL
induced	NULL
otherwise	NULL
unresponsive	NULL
B	NULL
cells	NULL
to	NULL
be	NULL
sensitive	NULL
to	NULL
CD40-dependent	NULL
SAPK	NULL
activation	NULL
.	NULL

Pre-treating	NULL
tonsillar	NULL
B	NULL
cells	NULL
with	NULL
either	NULL
heterologous	NULL
F	NULL
(	NULL
ab	NULL
'	NULL
)	NULL
,	NULL
anti-IgM	NULL
antisera	NULL
or	NULL
IL-4	NULL
had	NULL
the	NULL
same	NULL
effect	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

This	NULL
model	NULL
is	NULL
supported	NULL
further	NULL
by	NULL
our	NULL
preliminary	NULL
data	NULL
that	NULL
buoyant	NULL
human	NULL
tonsillar	NULL
B	NULL
cells	NULL
are	NULL
more	NULL
responsive	NULL
to	NULL
CD40-dependent	NULL
SAPK	NULL
activation	NULL
than	NULL
dense	NULL
cells	NULL
.	NULL

To	NULL
define	NULL
how	NULL
activation	NULL
signals	NULL
make	NULL
normal	NULL
B	NULL
cells	NULL
more	NULL
responsive	NULL
to	NULL
CD40-induced	NULL
SAPK	NULL
activation	NULL
will	NULL
require	NULL
further	NULL
study	NULL
.	NULL

For	NULL
now	NULL
we	NULL
can	NULL
speculate	NULL
that	NULL
a	NULL
component	NULL
of	NULL
the	NULL
CD40-SAPK	NULL
pathway	NULL
may	NULL
be	NULL
missing	NULL
at	NULL
certain	NULL
activation	NULL
stages	NULL
of	NULL
B	NULL
cell	NULL
maturation	NULL
,	NULL
or	NULL
that	NULL
the	NULL
pathway	NULL
is	NULL
inhibited	NULL
.	NULL

We	NULL
proposed	NULL
previously	NULL
that	NULL
CD40	NULL
on	NULL
antigen-presenting	NULL
cells	NULL
and	NULL
CD28	NULL
on	NULL
T	NULL
cells	NULL
have	NULL
similar	NULL
signaling	NULL
properties	NULL
and	NULL
can	NULL
activate	NULL
each	NULL
other	NULL
's	NULL
pathways	NULL
in	NULL
a	NULL
reciprocal	NULL
dialog	NULL
(	NULL
Clark	NULL
and	NULL
Ledbetter	NULL
,	NULL
1994	NULL
)	NULL
.	NULL

Here	NULL
we	NULL
found	NULL
additional	NULL
similarities	NULL
in	NULL
these	NULL
pathways	NULL
:	NULL
CD40	NULL
(	NULL
Figure	NULL
5B	NULL
)	NULL
and	NULL
CD28	NULL
ligation	NULL
(	NULL
Chatta	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
both	NULL
activate	NULL
increases	NULL
in	NULL
c-jun	NULL
and	NULL
not	NULL
c-fos	NULL
mRNA	NULL
,	NULL
and	NULL
both	NULL
CD40	NULL
(	NULL
Figures	NULL
1-4	NULL
)	NULL
and	NULL
CD28	NULL
(	NULL
Su	NULL
et	NULL
al..	NULL
,	NULL
1994	NULL
)	NULL
are	NULL
involved	NULL
in	NULL
SAPK	NULL
activation	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
similar	NULL
to	NULL
CD40	NULL
on	NULL
certain	NULL
human	NULL
tonsillar	NULL
B	NULL
cells	NULL
,	NULL
ligation	NULL
of	NULL
CD28	NULL
by	NULL
itself	NULL
is	NULL
not	NULL
sufficient	NULL
to	NULL
activate	NULL
SAPK	NULL
in	NULL
the	NULL
T	NULL
cells	NULL
analyzed	NULL
so	NULL
far	NULL
but	NULL
depends	NULL
on	NULL
simultaneous	NULL
T	NULL
cell	NULL
receptor	NULL
(	NULL
TCR	NULL
)	NULL
signals	NULL
(	NULL
Su	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

However	NULL
,	NULL
in	NULL
contrast	NULL
to	NULL
B	NULL
cells	NULL
.	NULL

no	NULL
situation	NULL
has	NULL
been	NULL
described	NULL
for	NULL
T	NULL
cells	NULL
in	NULL
which	NULL
CD28	NULL
ligaton	NULL
by	NULL
itself	NULL
could	NULL
stimulate	NULL
SAPK	NULL
.	NULL

Also	NULL
,	NULL
unlike	NULL
in	NULL
T	NULL
cells	NULL
,	NULL
in	NULL
WEHI	NULL
231	NULL
cells	NULL
the	NULL
engagement	NULL
of	NULL
the	NULL
antigen	NULL
receptor	NULL
is	NULL
sufficient	NULL
for	NULL
SAPK	NULL
activation	NULL
(	NULL
Siebelt	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
.	NULL

CD4O0-dependent	NULL
activation	NULL
of	NULL
SAPK	NULL
seems	NULL
to	NULL
be	NULL
insensitive	NULL
to	NULL
CsA	NULL
(	NULL
Figure	NULL
6B	NULL
)	NULL
.	NULL

whereas	NULL
the	NULL
combination	NULL
of	NULL
TCR/CD28	NULL
ligation	NULL
leading	NULL
to	NULL
SAPK	NULL
activation	NULL
is	NULL
sensitive	NULL
to	NULL
this	NULL
drug	NULL
(	NULL
Su	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

The	NULL
data	NULL
.	NULL

however	NULL
.	NULL

are	NULL
not	NULL
yet	NULL
sufficient	NULL
to	NULL
determine	NULL
whether	NULL
the	NULL
differences	NULL
we	NULL
observe	NULL
for	NULL
SAPK	NULL
recruitment	NULL
in	NULL
B	NULL
and	NULL
T	NULL
cells	NULL
reflect	NULL
differences	NULL
in	NULL
T	NULL
versus	NULL
B	NULL
cells	NULL
or	NULL
are	NULL
due	NULL
to	NULL
distinct	NULL
requirements	NULL
for	NULL
induction	NULL
of	NULL
SAPK	NULL
at	NULL
specific	NULL
activation/maturation	NULL
stages	NULL
.	NULL

The	NULL
finding	NULL
that	NULL
CD40	NULL
and	NULL
the	NULL
BCR	NULL
are	NULL
not	NULL
always	NULL
strong	NULL
inducers	NULL
of	NULL
SAPK	NULL
by	NULL
themselves	NULL
and	NULL
can	NULL
cooperate	NULL
in	NULL
certain	NULL
B	NULL
cells	NULL
supports	NULL
the	NULL
latter	NULL
notion	NULL
.	NULL

Materials	NULL
and	NULL
methods	NULL
Cells	NULL
Cell	NULL
culture	NULL
conditions	NULL
were	NULL
described	NULL
previously	NULL
(	NULL
Berberich	NULL
et	NULL
a/..	NULL
1994	NULL
)	NULL
.	NULL

Daudi	NULL
.	NULL

CESS	NULL
and	NULL
WEHI	NULL
231	NULL
were	NULL
obtained	NULL
from	NULL
American	NULL
Type	NULL
Culture	NULL
Collection	NULL
.	NULL

DND39	NULL
(	NULL
Ichiki	NULL
er	NULL
a/..	NULL
1992	NULL
)	NULL
and	NULL
BI04	NULL
(	NULL
Ishigami	NULL
et	NULL
al..	NULL
1992	NULL
)	NULL
cells	NULL
were	NULL
kindly	NULL
provided	NULL
by	NULL
Dr	NULL
T.Watanabe	NULL
and	NULL
Dr	NULL
M.Mayumi	NULL
.	NULL

respectively	NULL
.	NULL

The	NULL
M12	NULL
and	NULL
MI2/CD4O0	NULL
B	NULL
cell	NULL
lines	NULL
are	NULL
described	NULL
elsewhere	NULL
(	NULL
Inui	NULL
er	NULL
al..	NULL
1990	NULL
)	NULL
.	NULL

Tonsils	NULL
from	NULL
children	NULL
were	NULL
minced	NULL
,	NULL
then	NULL
live	NULL
mononuclear	NULL
cells	NULL
were	NULL
collected	NULL
on	NULL
a	NULL
Ficoll	NULL
gradient	NULL
and	NULL
.	NULL

after	NULL
two	NULL
washes	NULL
.	NULL

plated	NULL
at	NULL
2.5-5	NULL
x10	NULL
``	NULL
cells/ml	NULL
in	NULL
RPML	NULL
1640	NULL
supplemented	NULL
as	NULL
described	NULL
(	NULL
Clark	NULL
er	NULL
a/..	NULL
1989	NULL
;	NULL
Berberich	NULL
er	NULL
al..	NULL
1994	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
kept	NULL
at	NULL
25	NULL
or	NULL
37°C	NULL
with	NULL
or	NULL
without	NULL
PMA	NULL
stimulus	NULL
for	NULL
12-16	NULL
h.	NULL
Then	NULL
.	NULL

T	NULL
cells	NULL
were	NULL
rosetted	NULL
with	NULL
2-aminoethylisothiouranium	NULL
bromide	NULL
(	NULL
AET	NULL
sheep	NULL
red	NULL
blood	NULL
cells	NULL
as	NULL
described	NULL
(	NULL
Clark	NULL
et	NULL
aZ..	NULL
1989	NULL
)	NULL
and	NULL
removed	NULL
by	NULL
Ficoll	NULL
gradient	NULL
.	NULL

The	NULL
remaining	NULL
cells	NULL
were	NULL
size	NULL
fractionated	NULL
on	NULL
a	NULL
discontinuous	NULL
Percoll	NULL
gradient	NULL
.	NULL

Cells	NULL
>	NULL
55	NULL
%	NULL
were	NULL
used	NULL
in	NULL
the	NULL
experiments	NULL
.	NULL

B	NULL
cells	NULL
were	NULL
kept	NULL
at	NULL
37°C	NULL
in	NULL
medium	NULL
for	NULL
2-3	NULL
h	NULL
before	NULL
stimulation	NULL
.	NULL

Reagents	NULL
The	NULL
following	NULL
mAbs	NULL
were	NULL
used	NULL
in	NULL
this	NULL
study	NULL
:	NULL
G28-5	NULL
mAb	NULL
(	NULL
IgG1	NULL
)	NULL
to	NULL
CD40	NULL
(	NULL
Clark	NULL
and	NULL
Ledbetter	NULL
.	NULL

1986	NULL
)	NULL
.	NULL

G19-4	NULL
(	NULL
IgG1	NULL
)	NULL
to	NULL
CD3	NULL
(	NULL
Ledbetter	NULL
et	NULL
al..	NULL
1985	NULL
)	NULL
.	NULL

G28-7	NULL
(	NULL
IgG1	NULL
)	NULL
to	NULL
anti-CD22	NULL
(	NULL
Leprince	NULL
er	NULL
al..	NULL
1993	NULL
)	NULL
and	NULL
G28-1	NULL
(	NULL
IgGl	NULL
)	NULL
to	NULL
CD37	NULL
(	NULL
Ledbetter	NULL
er	NULL
al..	NULL
1987	NULL
)	NULL
.	NULL

1C10	NULL
to	NULL
anti-mouse	NULL
CD40	NULL
is	NULL
described	NULL
by	NULL
Heath	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
.	NULL

The	NULL
polyclonal	NULL
antisera	NULL
[	NULL
JNK	NULL
1	NULL
(	NULL
C-17	NULL
)	NULL
.	NULL

JNK2	NULL
(	NULL
C-18	NULL
)	NULL
,	NULL
ERKI	NULL
(	NULL
C-16	NULL
)	NULL
.	NULL

ERK2	NULL
(	NULL
C-14	NULL
)	NULL
.	NULL

ATF2	NULL
(	NULL
C-19	NULL
)	NULL
and	NULL
rac2	NULL
(	NULL
C-11	NULL
)	NULL
]	NULL
used	NULL
for	NULL
protein	NULL
kinase	NULL
assays	NULL
and	NULL
Western	NULL
blotting	NULL
were	NULL
purchased	NULL
from	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
(	NULL
Santa	NULL
Cruz	NULL
.	NULL

CA	NULL
)	NULL
.	NULL

except	NULL
for	NULL
the	NULL
anti-p54	NULL
SAPK	NULL
polyclonal	NULL
antisera	NULL
(	NULL
Kyriakis	NULL
er	NULL
al..	NULL
1994	NULL
)	NULL
.	NULL

Soluble	NULL
mouse	NULL
CD4O0L	NULL
was	NULL
prepared	NULL
using	NULL
a	NULL
vector	NULL
kindly	NULL
provided	NULL
by	NULL
Dr	NULL
Peter	NULL
Lane	NULL
as	NULL
described	NULL
(	NULL
Lane	NULL
et	NULL
al..	NULL
1993	NULL
)	NULL
.	NULL

MBP	NULL
was	NULL
obtained	NULL
from	NULL
UBI	NULL
.	NULL

CsA	NULL
was	NULL
a	NULL
gift	NULL
from	NULL
Sandoz	NULL
.	NULL

Transfection	NULL
and	NULL
CAT	NULL
assay	NULL
Daudi	NULL
and	NULL
M12/CD40	NULL
cells	NULL
were	NULL
transiently	NULL
transfected	NULL
by	NULL
means	NULL
of	NULL
the	NULL
DEAE-dextran	NULL
method	NULL
(	NULL
Berberich	NULL
et	NULL
al..	NULL
1994	NULL
)	NULL
.	NULL

Routinely	NULL
.	NULL

cells	NULL
were	NULL
stimulated	NULL
20-24	NULL
h	NULL
after	NULL
transfection	NULL
and	NULL
harvested	NULL
16-24	NULL
h	NULL
later	NULL
.	NULL

For	NULL
the	NULL
CAT	NULL
assay	NULL
,	NULL
transfected	NULL
cells	NULL
were	NULL
lysed	NULL
in	NULL
reporter	NULL
lysis	NULL
buffer	NULL
Cross-linking	NULL
CD40	NULL
activates	NULL
SAPK	NULL
(	NULL
100	NULL
ud	NULL
:	NULL
Promega	NULL
)	NULL
for	NULL
15	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

Lysates	NULL
were	NULL
cleared	NULL
by	NULL
centrifugation	NULL
and	NULL
incubated	NULL
for	NULL
up	NULL
to	NULL
8	NULL
h	NULL
in	NULL
a	NULL
reaction	NULL
mixture	NULL
(	NULL
125	NULL
ul	NULL
)	NULL
containing	NULL
200	NULL
uM	NULL
acetyl	NULL
coenzyme	NULL
A	NULL
and	NULL
25	NULL
nCi	NULL
[	NULL
``	NULL
C	NULL
}	NULL
chloram-phenicol	NULL
(	NULL
25	NULL
uCi/ml	NULL
)	NULL
.	NULL

[	NULL
'*C	NULL
)	NULL
Chloramphenicol	NULL
was	NULL
extracted	NULL
from	NULL
the	NULL
aqueous	NULL
solution	NULL
with	NULL
ethylacetate	NULL
(	NULL
400	NULL
pl	NULL
)	NULL
.	NULL

vacuum	NULL
dried	NULL
and	NULL
dissolved	NULL
in	NULL
20	NULL
ul	NULL
of	NULL
ethylacetate	NULL
.	NULL

The	NULL
diversely	NULL
acetylated	NULL
forms	NULL
of	NULL
[	NULL
°C	NULL
Jchloram-phenicol	NULL
were	NULL
separated	NULL
by	NULL
thin	NULL
layer	NULL
chromotography	NULL
.	NULL

The	NULL
following	NULL
plasmids	NULL
were	NULL
used	NULL
:	NULL
5	NULL
%	NULL
SRE-FOS-CAT/wt	NULL
(	NULL
five	NULL
copies	NULL
of	NULL
the	NULL
SRE	NULL
of	NULL
the	NULL
c-fos	NULL
promoter	NULL
linked	NULL
to	NULL
a	NULL
minimal	NULL
c-fos	NULL
promoter	NULL
)	NULL
,	NULL
5	NULL
%	NULL
SRE-FOS-CAT/pm12	NULL
(	NULL
as	NULL
wt	NULL
except	NULL
that	NULL
the	NULL
serum	NULL
response	NULL
factor	NULL
binding	NULL
site	NULL
of	NULL
the	NULL
SRE	NULL
was	NULL
mutated	NULL
)	NULL
(	NULL
Lee	NULL
and	NULL
Gilman	NULL
,	NULL
1994	NULL
)	NULL
,	NULL
pBL2	NULL
7+	NULL
{	NULL
contains	NULL
seven	NULL
copies	NULL
of	NULL
the	NULL
NF-xB	NULL
binding	NULL
site	NULL
from	NULL
the	NULL
promoter	NULL
of	NULL
the	NULL
invariant	NULL
chain	NULL
of	NULL
MHC	NULL
class	NULL
II	NULL
in	NULL
front	NULL
of	NULL
the	NULL
thymidine	NULL
kinase	NULL
(	NULL
tk	NULL
)	NULL
minimal	NULL
promoter	NULL
(	NULL
Pessara	NULL
and	NULL
Koch	NULL
.	NULL

1990	NULL
)	NULL
]	NULL
.	NULL

and	NULL
5	NULL
%	NULL
TREcol	NULL
(	NULL
five	NULL
copies	NULL
of	NULL
the	NULL
TRE	NULL
site	NULL
found	NULL
in	NULL
the	NULL
human	NULL
collagenase	NULL
promoter	NULL
linked	NULL
to	NULL
tk	NULL
and	NULL
CAT	NULL
)	NULL
.	NULL

Immunoprecipitations	NULL
,	NULL
protein	NULL
kinase	NULL
assays	NULL
and	NULL
Western	NULL
blotting	NULL
Immune	NULL
complex	NULL
kinase	NULL
assay	NULL
.	NULL

Following	NULL
stimulation	NULL
.	NULL

,	NULL
cells	NULL
(	NULL
3-10	NULL
x	NULL
10°	NULL
)	NULL
were	NULL
lysed	NULL
in	NULL
300-500	NULL
ul	NULL
of	NULL
kinase	NULL
lysis	NULL
buffer	NULL
[	NULL
20	NULL
mM	NULL
HEPES	NULL
.	NULL

pH	NULL
7.4	NULL
;	NULL
2	NULL
mM	NULL
EGTA	NULL
:	NULL
50	NULL
mM	NULL
B-glycerophosphate	NULL
:	NULL
1	NULL
%	NULL
Triton	NULL
X-100	NULL
;	NULL
10	NULL
%	NULL
glycerol	NULL
:	NULL
1	NULL
mM	NULL
dithiothreitol	NULL
(	NULL
DTT	NULL
)	NULL
2	NULL
mM	NULL
phenylmethylsulfony	NULL
]	NULL
fluoride	NULL
(	NULL
PMSF	NULL
)	NULL
:	NULL
1	NULL
ug/m	NULL
!	NULL

leupeptin	NULL
:	NULL
1	NULL
ug/ml	NULL
aprotinin	NULL
:	NULL
2	NULL
mM	NULL
Na	NULL
;	NULL
VOqy	NULL
:	NULL
and	NULL
10	NULL
mM	NULL
NaF	NULL
]	NULL
for	NULL
15	NULL
min	NULL
on	NULL
ice	NULL
.	NULL

[	NULL
To	NULL
detect	NULL
SAPK	NULL
activity	NULL
in	NULL
the	NULL
cytoplasm	NULL
.	NULL

cells	NULL
were	NULL
lysed	NULL
in	NULL
50	NULL
pl	NULL
lysis	NULL
buffer	NULL
(	NULL
Dignam	NULL
er	NULL
al..	NULL
1983	NULL
)	NULL
.	NULL

Nuclei	NULL
were	NULL
removed	NULL
by	NULL
centrifugation	NULL
and	NULL
the	NULL
cytoplasmic	NULL
extract	NULL
was	NULL
combined	NULL
with	NULL
450	NULL
pul	NULL
of	NULL
kinase	NULL
lysis	NULL
buffer	NULL
.	NULL
]	NULL

Cell	NULL
debris	NULL
was	NULL
removed	NULL
by	NULL
centrifugation	NULL
at	NULL
10	NULL
000	NULL
g	NULL
for	NULL
10	NULL
min	NULL
at	NULL
4°C	NULL
.	NULL

Kinases	NULL
(	NULL
SAPK	NULL
and/or	NULL
and	NULL
ERK2	NULL
)	NULL
were	NULL
immunoprecipitated	NULL
with	NULL
0.5	NULL
ug	NULL
of	NULL
polyclonal	NULL
antisera	NULL
(	NULL
in	NULL
the	NULL
case	NULL
of	NULL
SAPK	NULL
.	NULL

always	NULL
JNK1	NULL
C-17	NULL
,	NULL
except	NULL
for	NULL
part	NULL
of	NULL
the	NULL
experiment	NULL
shown	NULL
in	NULL
Figure	NULL
4B	NULL
)	NULL
and	NULL
20	NULL
pul	NULL
of	NULL
protein	NULL
A-Sepharose	NULL
beads	NULL
for	NULL
3-16	NULL
h.	NULL
Beads	NULL
were	NULL
washed	NULL
twice	NULL
each	NULL
with	NULL
kinase	NULL
lysis	NULL
buffer	NULL
.	NULL

high	NULL
salt	NULL
buffer	NULL
(	NULL
100	NULL
mM	NULL
Tris	NULL
pH	NULL
7.6	NULL
.	NULL

500	NULL
mM	NULL
LiCl	NULL
.	NULL

0.1	NULL
%	NULL
Triton	NULL
X-100	NULL
and	NULL
1	NULL
mM	NULL
DTT	NULL
)	NULL
,	NULL
and	NULL
assay	NULL
buffer	NULL
(	NULL
20	NULL
mM	NULL
MOPS	NULL
pH	NULL
7.2	NULL
;	NULL
2	NULL
mM	NULL
EGTA	NULL
:	NULL
10	NULL
mM	NULL
MgCls	NULL
:	NULL
0.1	NULL
%	NULL
Triton	NULL
X-100	NULL
and	NULL
1	NULL
mM	NULL
DTT	NULL
)	NULL
.	NULL

After	NULL
the	NULL
last	NULL
wash	NULL
,	NULL
beads	NULL
were	NULL
left	NULL
as	NULL
a	NULL
1+1	NULL
suspension	NULL
in	NULL
assay	NULL
buffer	NULL
.	NULL

Kinase	NULL
reactions	NULL
were	NULL
carried	NULL
out	NULL
at	NULL
30°C	NULL
for	NULL
20	NULL
min	NULL
after	NULL
addition	NULL
of	NULL
20	NULL
ul	NULL
of	NULL
substrate	NULL
(	NULL
1-3	NULL
ug	NULL
of	NULL
fusion	NULL
protein	NULL
or	NULL
MBP	NULL
in	NULL
assay	NULL
buffer	NULL
)	NULL
and	NULL
15	NULL
ul	NULL
of	NULL
ATP	NULL
mix	NULL
(	NULL
50	NULL
mM	NULL
MgCl	NULL
;	NULL
,	NULL
200	NULL
uM	NULL
ATP	NULL
and	NULL
5-10	NULL
uCi	NULL
[	NULL
y-°P	NULL
]	NULL
JATP	NULL
)	NULL
.	NULL

Reactions	NULL
were	NULL
stopped	NULL
by	NULL
adding	NULL
25	NULL
ul	NULL
of	NULL
6X	NULL
Laemmli	NULL
buffer	NULL
and	NULL
boiling	NULL
for	NULL
5	NULL
min	NULL
.	NULL

Samples	NULL
were	NULL
fractionated	NULL
on	NULL
an	NULL
SDS-polyacrylamide	NULL
gel	NULL
.	NULL

Autoradiography	NULL
was	NULL
performed	NULL
after	NULL
the	NULL
gels	NULL
were	NULL
dry	NULL
.	NULL

In-gel	NULL
kinase	NULL
assay	NULL
.	NULL

Lysis	NULL
and	NULL
immunoprecipitation	NULL
were	NULL
done	NULL
as	NULL
described	NULL
above	NULL
.	NULL

Kinase	NULL
precipitates	NULL
were	NULL
fractionated	NULL
on	NULL
an	NULL
SDS-polyacrylamide	NULL
gel	NULL
casted	NULL
with	NULL
the	NULL
respective	NULL
substrate	NULL
(	NULL
s	NULL
)	NULL
(	NULL
GST-c-Jun	NULL
,	NULL
GST-c-Jun/nb	NULL
and/or	NULL
MBP	NULL
:	NULL
40	NULL
ug/ml	NULL
)	NULL
.	NULL

The	NULL
remaining	NULL
steps	NULL
(	NULL
washes	NULL
,	NULL
denaturing	NULL
and	NULL
renaturing	NULL
steps	NULL
and	NULL
protein	NULL
kinase	NULL
assay	NULL
)	NULL
were	NULL
done	NULL
as	NULL
described	NULL
by	NULL
Hibi	NULL
er	NULL
al	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
.	NULL

Western	NULL
blotting	NULL
.	NULL

Cells	NULL
were	NULL
lysed	NULL
in	NULL
RIPA	NULL
buffer	NULL
(	NULL
10	NULL
mM	NULL
Tris	NULL
pH	NULL
8.0	NULL
.	NULL

50	NULL
mM	NULL
B-glycerophosphate	NULL
.	NULL

150	NULL
mM	NULL
NaCl	NULL
.	NULL

0.5	NULL
mM	NULL
EDTA	NULL
.	NULL

1	NULL
%	NULL
NP-40	NULL
,	NULL
0.5	NULL
%	NULL
deoxycholate	NULL
.	NULL

0.1	NULL
%	NULL
SDS	NULL
)	NULL
supplemented	NULL
with	NULL
PMSF	NULL
(	NULL
2	NULL
mM	NULL
)	NULL
.	NULL

pepstatin	NULL
(	NULL
1	NULL
ug/ml	NULL
)	NULL
,	NULL
leupeptin	NULL
(	NULL
1	NULL
ug/ml	NULL
)	NULL
.	NULL

aprotinin	NULL
(	NULL
1	NULL
ug/ml	NULL
)	NULL
.	NULL

soybean	NULL
trypsin	NULL
inhibitor	NULL
(	NULL
100	NULL
ug/ml	NULL
)	NULL
.	NULL

Na	NULL
;	NULL
VO4	NULL
(	NULL
2	NULL
mM	NULL
)	NULL
.	NULL

NaF	NULL
(	NULL
10	NULL
mM	NULL
)	NULL
and	NULL
DTT	NULL
(	NULL
1	NULL
mM	NULL
)	NULL
.	NULL

Immunoprecipitation	NULL
and	NULL
SDS-PAGE	NULL
were	NULL
performed	NULL
as	NULL
outlined	NULL
above	NULL
.	NULL

Proteins	NULL
were	NULL
transferred	NULL
to	NULL
nitrocellulose	NULL
membranes	NULL
using	NULL
standard	NULL
techniques	NULL
.	NULL

and	NULL
specific	NULL
proteins	NULL
were	NULL
detected	NULL
using	NULL
the	NULL
ECL	NULL
kit	NULL
(	NULL
Amersham	NULL
}	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
manual	NULL
.	NULL

Northern	NULL
blots	NULL
RNA	NULL
extractions	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
by	NULL
Chomezynski	NULL
and	NULL
Sacchi	NULL
(	NULL
1987	NULL
)	NULL
.	NULL

Up	NULL
to	NULL
5X10°	NULL
cells	NULL
were	NULL
lysed	NULL
in	NULL
0.5	NULL
ml	NULL
of	NULL
4	NULL
M	NULL
guanidinium	NULL
thiocyanate	NULL
.	NULL

Isolated	NULL
RNA	NULL
was	NULL
denatured	NULL
in	NULL
formaldehyde/	NULL
formamide	NULL
buffer	NULL
,	NULL
fractionated	NULL
on	NULL
a	NULL
conventional	NULL
formaldehyde-agarose	NULL
gel	NULL
.	NULL

and	NULL
transferred	NULL
to	NULL
a	NULL
membrane	NULL
.	NULL

Hybridization	NULL
was	NULL
performed	NULL
in	NULL
10	NULL
%	NULL
dextran	NULL
sulfate	NULL
at	NULL
65°C	NULL
with	NULL
*°P-labeled	NULL
cDNA	NULL
probes	NULL
(	NULL
random	NULL
labeling	NULL
kit	NULL
:	NULL
Boehringer	NULL
Mannheim	NULL
)	NULL
specific	NULL
for	NULL
c-jun	NULL
.	NULL

c-fos	NULL
and	NULL
B-actin	NULL
.	NULL

Production	NULL
and	NULL
purification	NULL
of	NULL
GST	NULL
fusion	NULL
proteins	NULL
GST-c-Jun	NULL
(	NULL
5-89	NULL
)	NULL
and	NULL
GST-c-Jun/nb	NULL
[	NULL
as	NULL
GST-c-Jun	NULL
(	NULL
5-89	NULL
)	NULL
but	NULL
with	NULL
the	NULL
8	NULL
domain	NULL
deleted	NULL
)	NULL
are	NULL
described	NULL
elsewhere	NULL
(	NULL
Kyriakis	NULL
et	NULL
al..	NULL
1994	NULL
)	NULL
.	NULL

The	NULL
cytoplasmic	NULL
tail	NULL
of	NULL
mouse	NULL
CD40	NULL
(	NULL
amino	NULL
acids	NULL
216-289	NULL
)	NULL
was	NULL
amplified	NULL
from	NULL
the	NULL
mCD40	NULL
cDNA-N	NULL
clone	NULL
(	NULL
Torres	NULL
and	NULL
Clark	NULL
.	NULL

1992	NULL
)	NULL
by	NULL
PCR	NULL
and	NULL
was	NULL
cloned	NULL
in-frame	NULL
into	NULL
the	NULL
pGEX-2T	NULL
expression	NULL
vector	NULL
(	NULL
Pharmacia	NULL
)	NULL
using	NULL
the	NULL
EcoRI	NULL
and	NULL
BamHI	NULL
restriction	NULL
sites	NULL
.	NULL

Fusion	NULL
proteins	NULL
were	NULL
expressed	NULL
in	NULL
Escherichia	NULL
coli	NULL
BL21	NULL
(	NULL
DE3	NULL
)	NULL
.	NULL

Expression	NULL
of	NULL
the	NULL
fusion	NULL
99	NULL
.Berberich	NULL
et	NULL
al	NULL
.	NULL

proteins	NULL
was	NULL
induced	NULL
in	NULL
exponentially	NULL
growing	NULL
bacteria	NULL
(	NULL
ODsqyp	NULL
~0.5	NULL
)	NULL
with	NULL
0.1	NULL
mM	NULL
IPTG	NULL
for	NULL
2-4	NULL
h.	NULL
After	NULL
centrifugation	NULL
,	NULL
bacteria	NULL
were	NULL
resuspended	NULL
in	NULL
lysis	NULL
buffer	NULL
[	NULL
PBS	NULL
,	NULL
0.1	NULL
%	NULL
Triton	NULL
X-100	NULL
with	NULL
PMSF	NULL
(	NULL
2	NULL
mM	NULL
)	NULL
.	NULL

pepstatin	NULL
(	NULL
1	NULL
ug/ml	NULL
)	NULL
,	NULL
leupeptin	NULL
(	NULL
1	NULL
ug/ml	NULL
)	NULL
,	NULL
aprotinin	NULL
(	NULL
1	NULL
ug/ml	NULL
)	NULL
,	NULL
soybean	NULL
trypsin	NULL
inhibitor	NULL
(	NULL
100	NULL
ug/ml	NULL
)	NULL
and	NULL
DTT	NULL
(	NULL
1	NULL
mM	NULL
)	NULL
]	NULL
before	NULL
sonication	NULL
.	NULL

Fusion	NULL
proteins	NULL
were	NULL
collected	NULL
from	NULL
the	NULL
cleared	NULL
lysate	NULL
by	NULL
glutathione	NULL
,	NULL
agarose	NULL
chromatography	NULL
and	NULL
released	NULL
from	NULL
the	NULL
agarose	NULL
with	NULL
5	NULL
mM	NULL
glutathione	NULL
.	NULL

Proteins	NULL
were	NULL
dialyzed	NULL
against	NULL
50	NULL
mM	NULL
Tris	NULL
pH	NULL
7.9	NULL
and	NULL
stored	NULL
as	NULL
50	NULL
%	NULL
glycerol	NULL
solution	NULL
at	NULL
-20°C	NULL
.	NULL

Nuclear	NULL
extracts	NULL
and	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
sssay	NULL
Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
as	NULL
described	NULL
by	NULL
Dignam	NULL
er	NULL
al	NULL
.	NULL

(	NULL
1983	NULL
)	NULL
.	NULL

Electrophoretic	NULL
mobility	NULL
shift	NULL
assays	NULL
were	NULL
performed	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
Berberich	NULL
er	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

Acknowledgements	NULL
We	NULL
thank	NULL
Drs	NULL
M.Gilman	NULL
and	NULL
E.Serfling	NULL
for	NULL
plasmids	NULL
,	NULL
Drs	NULL
M.Howard	NULL
and	NULL
A.Heath	NULL
for	NULL
the	NULL
anti-mCD40	NULL
mAb	NULL
,	NULL
Dr	NULL
S.J.Klaus	NULL
for	NULL
providing	NULL
the	NULL
CD4OL	NULL
fusion	NULL
protein	NULL
,	NULL
Dr	NULL
C.-L.Law	NULL
for	NULL
helpful	NULL
discussions	NULL
,	NULL
and	NULL
M.Domenowske	NULL
and	NULL
K.Elias	NULL
for	NULL
graphic	NULL
and	NULL
editorial	NULL
assistance	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
NIH	NULL
grants	NULL
GM37905	NULL
and	NULL
RRO0166	NULL
.	NULL

LB	NULL
.	NULL

was	NULL
supported	NULL
by	NULL
the	NULL
Bundesministerium	NULL
fiir	NULL
Forschung	NULL
und	NULL
Technologie	NULL
.	NULL

References	NULL
Adler	NULL
,	NULL
V.	NULL
,	NULL
Franklin	NULL
,	NULL
C.C	NULL
.	NULL

and	NULL
Kraft	NULL
,	NULL
.	NULL

A.S.	NULL
(	NULL
1992	NULL
)	NULL
Phorbol	NULL
esters	NULL
stimulate	NULL
the	NULL
phosphorylation	NULL
of	NULL
c-Jun	NULL
but	NULL
not	NULL
v-Jun	NULL
:	NULL
regulation	NULL
by	NULL
the	NULL
N-terminal	NULL
delta	NULL
domain	NULL
.	NULL

Proc	NULL
.	NULL

Nat	NULL
!	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
89	NULL
,	NULL
5341-5345	NULL
.	NULL

Alderson	NULL
,	NULL
Armitage	NULL
,	NULL
R.J.	NULL
,	NULL
Tough	NULL
,	NULL
T.W	NULL
.	NULL

,	NULL
Strockbine	NULL
,	NULL
L..	NULL
,	NULL
Fanslow	NULL
,	NULL
W.C.	NULL
and	NULL
Spriggs	NULL
.	NULL

M.K	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
CD40	NULL
expression	NULL
by	NULL
human	NULL
monocytes	NULL
:	NULL
regulation	NULL
by	NULL
cytokines	NULL
and	NULL
activation	NULL
of	NULL
monocytes	NULL
by	NULL
the	NULL
ligand	NULL
for	NULL
CD40	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
178	NULL
,	NULL
669-674	NULL
.	NULL

Angel	NULL
,	NULL
P.	NULL
,	NULL
Hattori	NULL
,	NULL
K.	NULL
,	NULL
Smeal	NULL
,	NULL
T	NULL
.	NULL

and	NULL
Karin	NULL
,	NULL
M	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
The	NULL
jun	NULL
proto-oncogene	NULL
is	NULL
positively	NULL
autoregulated	NULL
by	NULL
its	NULL
product	NULL
,	NULL
Jun/AP-1	NULL
.	NULL

Cel/	NULL
,	NULL
55	NULL
,	NULL
875-885	NULL
.	NULL

Armitage	NULL
,	NULL
R.J	NULL
.	NULL

et	NULL
al	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Molecular	NULL
and	NULL
biological	NULL
characterization	NULL
of	NULL
a	NULL
murine	NULL
ligand	NULL
for	NULL
CD40	NULL
.	NULL

Nature	NULL
,	NULL
357	NULL
,	NULL
80-82	NULL
.	NULL

Banchereau	NULL
,	NULL
J.	NULL
,	NULL
Bazan	NULL
,	NULL
F.	NULL
,	NULL
Blanchard	NULL
,	NULL
.D	NULL
.	NULL

,	NULL
Briere.F	NULL
.	NULL

,	NULL
GalizziJ.P	NULL
.	NULL

,	NULL
van	NULL
Kooten	NULL
,	NULL
C.	NULL
,	NULL
Liu	NULL
,	NULL
Y.J	NULL
.	NULL

,	NULL
Rousset.F	NULL
.	NULL

and	NULL
Saeland	NULL
.	NULL

$	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
The	NULL
CD40	NULL
antigen	NULL
and	NULL
its	NULL
ligand	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
12	NULL
,	NULL
881-922	NULL
.	NULL

Berberich,1	NULL
.	NULL

,	NULL
Shu	NULL
,	NULL
G.L	NULL
.	NULL

and	NULL
Clark	NULL
,	NULL
E.A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Cross-linking	NULL
CD40	NULL
on	NULL
B	NULL
cells	NULL
rapidly	NULL
activates	NULL
nuclear	NULL
factor-kappa	NULL
B.	NULL
J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
153	NULL
,	NULL
4357-4366	NULL
.	NULL

Bird	NULL
,	NULL
T.A	NULL
.	NULL

,	NULL
Kyriakis	NULL
,	NULL
J.M	NULL
.	NULL

,	NULL
Tyshler	NULL
,	NULL
L.	NULL
,	NULL
Gayle	NULL
,	NULL
M.	NULL
,	NULL
Milne	NULL
,	NULL
A	NULL
.	NULL

and	NULL
Virca	NULL
,	NULL
G.D	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Interleukin-1	NULL
activates	NULL
p54	NULL
mitogen-activated	NULL
protein	NULL
(	NULL
MAP	NULL
)	NULL
kinase/stress-activated	NULL
protein	NULL
kinase	NULL
by	NULL
a	NULL
pathway	NULL
that	NULL
is	NULL
independent	NULL
of	NULL
p2Iiras	NULL
,	NULL
Raf-1	NULL
,	NULL
and	NULL
MAP	NULL
kinase	NULL
kinase	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
269	NULL
,	NULL
31836-31844	NULL
.	NULL

Chatta	NULL
,	NULL
G.S	NULL
.	NULL

,	NULL
Spies	NULL
,	NULL
A.G.	NULL
,	NULL
Chang	NULL
,	NULL
S.	NULL
,	NULL
Mize	NULL
,	NULL
G.J	NULL
.	NULL

,	NULL
Linsley	NULL
,	NULL
P.S	NULL
.	NULL

,	NULL
Ledbetter	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
and	NULL
Morris	NULL
.	NULL

D.R	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Differential	NULL
regulation	NULL
of	NULL
proto-oncogenes	NULL
cjun	NULL
and	NULL
c-fos	NULL
in	NULL
T	NULL
lymphocytes	NULL
activated	NULL
through	NULL
CD28	NULL
.	NULL

J	NULL
.	NULL

/mmunol	NULL
.	NULL

,	NULL
153	NULL
,	NULL
5393-5401	NULL
.	NULL

Cheng	NULL
,	NULL
G.	NULL
,	NULL
Cleary	NULL
,	NULL
A.M.	NULL
,	NULL
Ye	NULL
,	NULL
Z.	NULL
,	NULL
Hong	NULL
,	NULL
D.1	NULL
.	NULL

,	NULL
Lederman	NULL
,	NULL
$	NULL
.	NULL

and	NULL
Baltimore.D	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Involvement	NULL
of	NULL
CRAFT	NULL
,	NULL
a	NULL
relative	NULL
of	NULL
TRAF	NULL
,	NULL
in	NULL
CD40	NULL
signaling	NULL
.	NULL

Science	NULL
,	NULL
267	NULL
,	NULL
1494-1498	NULL
.	NULL

Choi	NULL
,	NULL
S.K	NULL
.	NULL

,	NULL
Brines.R.D	NULL
.	NULL

,	NULL
Holman	NULL
,	NULL
M.J	NULL
.	NULL

and	NULL
Klaus	NULL
,	NULL
G.G.B	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Induction	NULL
of	NULL
NF-AT	NULL
in	NULL
normal	NULL
B	NULL
lymphocytes	NULL
by	NULL
anti-immunoglobulin	NULL
or	NULL
CD40	NULL
ligand	NULL
in	NULL
conjunction	NULL
with	NULL
IL-4	NULL
.	NULL

Immunity	NULL
,	NULL
1	NULL
,	NULL
179-187	NULL
.	NULL

Chomezynski	NULL
,	NULL
P	NULL
.	NULL

and	NULL
Sacchi.N	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Single-step	NULL
method	NULL
of	NULL
RNA	NULL
isolation	NULL
|	NULL
by	NULL
-	NULL
acid	NULL
-	NULL
guanidinium	NULL
-	NULL
thiocyanate-phenol-chloroform	NULL
extraction	NULL
.	NULL

Anal	NULL
.	NULL

Biochem	NULL
.	NULL

,	NULL
162	NULL
,	NULL
156-159	NULL
.	NULL

Clark	NULL
,	NULL
E.A	NULL
.	NULL

and	NULL
Ledbetter	NULL
,	NULL
J.A	NULL
.	NULL

(	NULL
1986	NULL
)	NULL
Activation	NULL
of	NULL
human	NULL
B	NULL
cells	NULL
mediated	NULL
through	NULL
two	NULL
distinct	NULL
cell	NULL
surface	NULL
differentiation	NULL
antigens	NULL
,	NULL
Bp35	NULL
and	NULL
Bp50	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
83	NULL
,	NULL
4494-4498	NULL
.	NULL

Clark	NULL
,	NULL
E.A	NULL
.	NULL

and	NULL
Ledbetter	NULL
,	NULL
J.A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
How	NULL
B	NULL
and	NULL
T	NULL
cells	NULL
talk	NULL
to	NULL
each	NULL
other	NULL
.	NULL

Nature	NULL
,	NULL
367	NULL
,	NULL
425-428	NULL
.	NULL

Clark	NULL
,	NULL
E.A	NULL
.	NULL

,	NULL
_	NULL
Shu	NULL
,	NULL
G.L	NULL
.	NULL

,	NULL
_	NULL
Luscher	NULL
,	NULL
B.	NULL
,	NULL
-	NULL
Draves.K.E	NULL
.	NULL

,	NULL
-	NULL
Banchereau.J	NULL
.	NULL

,	NULL
Ledbetter	NULL
,	NULL
J.A	NULL
.	NULL

and	NULL
Valentine	NULL
,	NULL
M.A	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Activation	NULL
of	NULL
human	NULL
B	NULL
cells	NULL
.	NULL

Comparison	NULL
of	NULL
the	NULL
signal	NULL
transduced	NULL
by	NULL
IL-4	NULL
to	NULL
four	NULL
different	NULL
competence	NULL
signals	NULL
.	NULL

J	NULL
.	NULL

/mmunol	NULL
.	NULL

,	NULL
143	NULL
,	NULL
3873-3880	NULL
.	NULL

Davis	NULL
,	NULL
R.J.	NULL
(	NULL
1994	NULL
)	NULL
MAPKs	NULL
:	NULL
new	NULL
JNK	NULL
expands	NULL
the	NULL
group	NULL
.	NULL

Trends	NULL
Biochem	NULL
.	NULL

Sci	NULL
.	NULL

,	NULL
19	NULL
,	NULL
470-473	NULL
.	NULL

Dérijard	NULL
,	NULL
B.	NULL
,	NULL
Hibi	NULL
,	NULL
M.	NULL
,	NULL
Wu	NULL
,	NULL
LH	NULL
.	NULL

,	NULL
Barrett.T	NULL
.	NULL

,	NULL
Su	NULL
,	NULL
B.	NULL
,	NULL
Deng.T..	NULL
Karin	NULL
,	NULL
M.	NULL
and	NULL
Davis	NULL
,	NULL
R.J	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
JNK	NULL
1	NULL
:	NULL
a	NULL
protein	NULL
kinase	NULL
stimulated	NULL
by	NULL
UV	NULL
light	NULL
and	NULL
100	NULL
Ha-Ras	NULL
that	NULL
binds	NULL
and	NULL
phosphorylates	NULL
the	NULL
c-Jun	NULL
activation	NULL
domain	NULL
.	NULL

Cell	NULL
,	NULL
76	NULL
,	NULL
1025-1037	NULL
.	NULL

Dignam	NULL
,	NULL
J.D..	NULL
Lebovitz.R.M	NULL
.	NULL

and	NULL
RoederR.G	NULL
.	NULL

(	NULL
1983	NULL
)	NULL
Accurate	NULL
transcription	NULL
initiation	NULL
by	NULL
RNA	NULL
polymerase	NULL
II	NULL
in	NULL
a	NULL
soluble	NULL
extract	NULL
from	NULL
isolated	NULL
mammalian	NULL
nuclei	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

,	NULL
11	NULL
,	NULL
1475-1489	NULL
.	NULL

Du	NULL
.	NULL

W.	NULL
,	NULL
Thanos.D	NULL
.	NULL

and	NULL
Maniatis.T	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Mechanisms	NULL
of	NULL
transcriptional	NULL
synergism	NULL
between	NULL
distinct	NULL
virus-inducible	NULL
enhancer	NULL
elements	NULL
.	NULL

Cell	NULL
,	NULL
74	NULL
,	NULL
887-898	NULL
.	NULL

Faris.M	NULL
.	NULL

,	NULL
Gaskin	NULL
,	NULL
F.	NULL
,	NULL
Parsons.J.T	NULL
.	NULL

and	NULL
Fu	NULL
,	NULL
S.M	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
CD40	NULL
signaling	NULL
pathway	NULL
:	NULL
anti-CD40	NULL
mAb	NULL
induces	NULL
rapid	NULL
dephosphorylation	NULL
and	NULL
phosphorylation	NULL
of	NULL
tyrosine-phosphorylated	NULL
proteins	NULL
including	NULL
protein	NULL
tyrosine	NULL
kinsase	NULL
Lyn	NULL
,	NULL
Fyn	NULL
and	NULL
Syk	NULL
and	NULL
the	NULL
appearance	NULL
of	NULL
a	NULL
28-kD	NULL
phosphorylated	NULL
protein	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
179	NULL
,	NULL
1923-1931	NULL
.	NULL

Francis	NULL
,	NULL
D.A..	NULL
Karras.J.G	NULL
.	NULL

,	NULL
Ke	NULL
,	NULL
.X	NULL
.	NULL

,	NULL
Sen	NULL
,	NULL
R	NULL
.	NULL

and	NULL
Rothstein	NULL
,	NULL
T.L	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Induction	NULL
of	NULL
the	NULL
transcription	NULL
factors	NULL
NF-kappaB	NULL
.	NULL

AP-	NULL
!	NULL

and	NULL
NF-AT	NULL
during	NULL
B	NULL
cell	NULL
stimulation	NULL
through	NULL
the	NULL
CD40	NULL
receptor	NULL
,	NULL
/nt	NULL
.	NULL

Immunol	NULL
.	NULL

7	NULL
,	NULL
151-161	NULL
.	NULL

Galy	NULL
,	NULL
A.H.	NULL
and	NULL
Spits	NULL
,	NULL
H	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
CD40	NULL
is	NULL
functionally	NULL
expressed	NULL
on	NULL
human	NULL
thymic	NULL
epithelial	NULL
cells	NULL
.	NULL

J	NULL
.	NULL

/mmunol	NULL
.	NULL

,	NULL
149	NULL
,	NULL
775-782	NULL
.	NULL

Gille	NULL
,	NULL
H.	NULL
,	NULL
Sharrocks	NULL
,	NULL
A.D	NULL
.	NULL

and	NULL
Shaw	NULL
,	NULL
PE	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Phosphorylation	NULL
of	NULL
transcription	NULL
factor	NULL
p62TCF	NULL
by	NULL
MAP	NULL
kinase	NULL
stimulates	NULL
ternary	NULL
complex	NULL
formation	NULL
at	NULL
the	NULL
c-fos	NULL
promoter	NULL
,	NULL
Nature	NULL
,	NULL
358	NULL
,	NULL
414-417	NULL
.	NULL

Gille	NULL
,	NULL
H.	NULL
,	NULL
-	NULL
Kortenjann	NULL
,	NULL
.M..	NULL
Thomae,0	NULL
.	NULL

,	NULL
Moomaw	NULL
,	NULL
C.	NULL
,	NULL
-	NULL
Slaughter.C	NULL
.	NULL

,	NULL
Cobb	NULL
,	NULL
M.H	NULL
.	NULL

and	NULL
Shaw	NULL
,	NULL
PE	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
ERK	NULL
phosphorylation	NULL
potentiates	NULL
-mediated	NULL
ternary	NULL
complex	NULL
formation	NULL
and	NULL
transactivation	NULL
.	NULL

EMBO	NULL
J.	NULL
,	NULL
14	NULL
,	NULL
951-962	NULL
.	NULL

Gupta	NULL
,	NULL
S.	NULL
,	NULL
Campbell	NULL
,	NULL
D.	NULL
,	NULL
Dérijard.B	NULL
.	NULL

and	NULL
Davis	NULL
,	NULL
R.J	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Transcription	NULL
factor	NULL
ATF2	NULL
regulation	NULL
by	NULL
the	NULL
JNK	NULL
signal	NULL
transduction	NULL
pathway	NULL
.	NULL

Science	NULL
,	NULL
267	NULL
,	NULL
389-393	NULL
.	NULL

Hart.D.N	NULL
.	NULL

and	NULL
McKenzie	NULL
,	NULL
J.L	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Isolation	NULL
and	NULL
characterization	NULL
of	NULL
human	NULL
tonsil	NULL
dendritic	NULL
cells	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
168	NULL
,	NULL
157-170	NULL
.	NULL

Heath	NULL
,	NULL
A.W	NULL
.	NULL

et	NULL
al	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Antibodies	NULL
to	NULL
murine	NULL
CD40	NULL
stimulate	NULL
normal	NULL
B	NULL
lymphocytes	NULL
but	NULL
inhibit	NULL
proliferation	NULL
of	NULL
B	NULL
lymphoma	NULL
cells	NULL
.	NULL

Cell	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
152	NULL
,	NULL
468-480	NULL
.	NULL

Hibi	NULL
,	NULL
M.	NULL
,	NULL
Lin	NULL
,	NULL
A.	NULL
,	NULL
Smeal.T	NULL
.	NULL

,	NULL
Minden	NULL
,	NULL
A	NULL
.	NULL

and	NULL
Karin	NULL
,	NULL
M.	NULL
(	NULL
1993	NULL
)	NULL
Identification	NULL
of	NULL
an	NULL
oncoprotein-	NULL
and	NULL
UV-responsive	NULL
protein	NULL
kinase	NULL
that	NULL
binds	NULL
and	NULL
potentiates	NULL
the	NULL
c-Jun	NULL
activation	NULL
domain	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

,	NULL
7	NULL
,	NULL
2135-2148	NULL
.	NULL

Hill	NULL
.	NULL

A.	NULL
and	NULL
Chapel.H	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
X-linked	NULL
immunodeficiency	NULL
.	NULL

The	NULL
fruits	NULL
of	NULL
cooperation	NULL
.	NULL

Nature	NULL
,	NULL
361	NULL
,	NULL
494	NULL
.	NULL

Hu	NULL
,	NULL
H.M.	NULL
,	NULL
O'Rourke	NULL
,	NULL
K.	NULL
,	NULL
Boguski	NULL
,	NULL
M.S	NULL
.	NULL

and	NULL
Dixit	NULL
,	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
A	NULL
novel	NULL
RING	NULL
finger	NULL
protein	NULL
interacts	NULL
with	NULL
the	NULL
cytoplasmic	NULL
domain	NULL
of	NULL
CD40	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
269	NULL
,	NULL
30069-30072	NULL
.	NULL

Ichiki	NULL
,	NULL
T.	NULL
,	NULL
Takahashi	NULL
,	NULL
W.	NULL
and	NULL
Watanabe	NULL
,	NULL
T	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
The	NULL
effect	NULL
of	NULL
cytokines	NULL
and	NULL
mitogens	NULL
on	NULL
the	NULL
induction	NULL
of	NULL
C	NULL
epsilon	NULL
germline	NULL
transcripts	NULL
in	NULL
a	NULL
human	NULL
Burkitt	NULL
lymphoma	NULL
B	NULL
cell	NULL
line	NULL
.	NULL

/nt	NULL
.	NULL

/mmunol	NULL
.	NULL

,	NULL
4	NULL
,	NULL
747-754	NULL
.	NULL

Inui.S	NULL
.	NULL

,	NULL
Kaisho	NULL
,	NULL
T.	NULL
,	NULL
Kikutani	NULL
,	NULL
H.	NULL
,	NULL
Stamenkovie	NULL
,	NULL
I.	NULL
,	NULL
Seed	NULL
,	NULL
B.	NULL
,	NULL
Clark	NULL
,	NULL
E.A	NULL
.	NULL

and	NULL
Kishimoto	NULL
,	NULL
T	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Identification	NULL
of	NULL
the	NULL
intracytoplasmic	NULL
region	NULL
essential	NULL
for	NULL
signal	NULL
transduction	NULL
through	NULL
a	NULL
B	NULL
cell	NULL
activation	NULL
molecule	NULL
,	NULL
CD40	NULL
.	NULL

Eur	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
20	NULL
,	NULL
1747-1753	NULL
.	NULL

Ishigami	NULL
,	NULL
T.	NULL
,	NULL
Kim.K.M	NULL
.	NULL

,	NULL
Horiguchi	NULL
,	NULL
Y.	NULL
,	NULL
Higaki	NULL
,	NULL
Y.	NULL
,	NULL
Hata	NULL
,	NULL
D.	NULL
,	NULL
Heike	NULL
,	NULL
T.	NULL
,	NULL
Katamura	NULL
,	NULL
K.	NULL
,	NULL
Mayumi	NULL
,	NULL
M.	NULL
and	NULL
Mikawa	NULL
,	NULL
H	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Anti-IgM	NULL
antibody-induced	NULL
cell	NULL
death	NULL
in	NULL
a	NULL
human	NULL
B	NULL
lymphoma	NULL
cell	NULL
line	NULL
,	NULL
B104	NULL
,	NULL
represents	NULL
a	NULL
novel	NULL
programmed	NULL
cell	NULL
death	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
148	NULL
,	NULL
360-368	NULL
.	NULL

Kawabe.T	NULL
.	NULL

,	NULL
Naka	NULL
,	NULL
T.	NULL
,	NULL
Yishida	NULL
,	NULL
K.	NULL
,	NULL
Tanaka	NULL
,	NULL
T.	NULL
,	NULL
Fujiwara	NULL
,	NULL
H.	NULL
,	NULL
Suematsu.S	NULL
.	NULL

,	NULL
Yoshida.N	NULL
.	NULL

,	NULL
Kishimoto	NULL
,	NULL
.T	NULL
.	NULL

and	NULL
Kikutani	NULL
,	NULL
H	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
The	NULL
immune	NULL
response	NULL
in	NULL
CD4O-deficient	NULL
mice	NULL
:	NULL
impaired	NULL
immunoglobulin	NULL
class	NULL
switching	NULL
and	NULL
germinal	NULL
center	NULL
formation	NULL
.	NULL

/mmunity	NULL
,	NULL
1	NULL
,	NULL
167-178	NULL
.	NULL

Klaus	NULL
,	NULL
S.J	NULL
.	NULL

,	NULL
Berberich	NULL
,	NULL
L	NULL
,	NULL
Shu	NULL
,	NULL
G	NULL
.	NULL

and	NULL
Clark	NULL
,	NULL
E.A	NULL
.	NULL

(	NULL
19942	NULL
)	NULL
CD40	NULL
and	NULL
its	NULL
ligand	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
humoral	NULL
immunity	NULL
.	NULL

Semin	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
6	NULL
,	NULL
279-286	NULL
Klaus	NULL
,	NULL
S.J	NULL
.	NULL

,	NULL
_	NULL
Pinchuk	NULL
,	NULL
L.M	NULL
.	NULL

,	NULL
_	NULL
Ochs	NULL
,	NULL
H.D	NULL
.	NULL

,	NULL
Law	NULL
,	NULL
C.L	NULL
.	NULL

,	NULL
_	NULL
Fanslow	NULL
,	NULL
.W.C	NULL
.	NULL

,	NULL
Armitage	NULL
,	NULL
R.J	NULL
.	NULL

and	NULL
Clark	NULL
,	NULL
E.A	NULL
.	NULL

(	NULL
1994b	NULL
)	NULL
Costimulation	NULL
through	NULL
CD28	NULL
enhances	NULL
T	NULL
cell-dependent	NULL
B	NULL
cell	NULL
activation	NULL
via	NULL
CD40-CD40L	NULL
interaction	NULL
.	NULL

J	NULL
.	NULL

/mmunol..	NULL
152	NULL
,	NULL
5643-5652	NULL
.	NULL

Knox	NULL
,	NULL
K.A	NULL
.	NULL

and	NULL
Gordon	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Protein	NULL
tyrosine	NULL
phosphorylation	NULL
is	NULL
mandatory	NULL
for	NULL
CD40-mediated	NULL
rescue	NULL
of	NULL
germinal	NULL
center	NULL
B	NULL
cells	NULL
from	NULL
apoptosis	NULL
.	NULL

Eur	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
23	NULL
,	NULL
2578-2584	NULL
.	NULL

Kolch	NULL
,	NULL
W..	NULL
Heidecker	NULL
,	NULL
G..	NULL
Kochs.G	NULL
.	NULL

,	NULL
Hummel	NULL
,	NULL
R.	NULL
,	NULL
Vahidi	NULL
,	NULL
H.	NULL
,	NULL
Mischak.H	NULL
.	NULL

,	NULL
Finkenzeller	NULL
,	NULL
G.	NULL
,	NULL
Marmé	NULL
,	NULL
D	NULL
.	NULL

and	NULL
Rapp.U.R	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Protein	NULL
kinase	NULL
C	NULL
alpha	NULL
activates	NULL
RAF-1	NULL
by	NULL
direct	NULL
phosphorylation	NULL
.	NULL

Nature	NULL
,	NULL
364	NULL
,	NULL
249-252	NULL
.	NULL

Kruppa	NULL
,	NULL
G.	NULL
,	NULL
Thoma	NULL
,	NULL
B.	NULL
,	NULL
Machleidt.T	NULL
.	NULL

,	NULL
Wiegmann	NULL
,	NULL
K	NULL
.	NULL

and	NULL
Kronke	NULL
,	NULL
M	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Inhibition	NULL
of	NULL
tumor	NULL
necrosis	NULL
factor	NULL
(	NULL
TNF	NULL
)	NULL
-mediated	NULL
NF-kappa	NULL
B	NULL
activation	NULL
by	NULL
selective	NULL
blockade	NULL
of	NULL
the	NULL
human	NULL
55-kDa	NULL
TNF	NULL
receptor	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
148	NULL
,	NULL
3152-3157	NULL
.	NULL

Kyriakis	NULL
,	NULL
J.M	NULL
.	NULL

,	NULL
_	NULL
Banerjee	NULL
,	NULL
P..	NULL
Nikotakaki	NULL
,	NULL
E.	NULL
,	NULL
_	NULL
Dai	NULL
,	NULL
T.	NULL
,	NULL
_	NULL
Rubie	NULL
,	NULL
E.A	NULL
.	NULL

,	NULL
Ahmad	NULL
.	NULL

M.F	NULL
.	NULL

,	NULL
Avruch.J	NULL
.	NULL

and	NULL
Woodgett.J.R	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
The	NULL
stress-activated	NULL
protein	NULL
kinase	NULL
subfamily	NULL
of	NULL
c-Jun	NULL
kinases	NULL
.	NULL

Nature	NULL
,	NULL
369	NULL
,	NULL
156-160	NULL
.	NULL

Lane.P..	NULL
Brocker.T..	NULL
Hubele.S..	NULL
Padovan.E	NULL
.	NULL

,	NULL
Lanzavecchia.A	NULL
.	NULL

and	NULL
McConnel.F	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Soluble	NULL
CD40	NULL
ligand	NULL
can	NULL
replace	NULL
the	NULL
normal	NULL
T	NULL
cell-derived	NULL
CD40	NULL
ligand	NULL
signal	NULL
to	NULL
B	NULL
cells	NULL
in	NULL
T	NULL
cell-dependent	NULL
activation	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
177	NULL
.	NULL

1209-1213	NULL
.	NULL

LedbetterJ.A..	NULL
Tsu.T.T..	NULL
Draves.K	NULL
.	NULL

and	NULL
Clark.E.A	NULL
.	NULL

(	NULL
1985	NULL
)	NULL
Differential	NULL
expression	NULL
of	NULL
pan	NULL
T	NULL
cell	NULL
antigens	NULL
on	NULL
human	NULL
T	NULL
cell	NULL
subsets	NULL
.	NULL

In	NULL
Heise.E	NULL
.	NULL

(	NULL
ed	NULL
.	NULL
)	NULL

.	NULL

Perspectives	NULL
in	NULL
Immunogenetics	NULL
and	NULL
Histocompatibility	NULL
,	NULL
Vol	NULL
.	NULL

6	NULL
,	NULL
Lymphocyte	NULL
Surface	NULL
Antigens	NULL
.	NULL

American	NULL
Society	NULL
of	NULL
Histocompatibility	NULL
and	NULL
Immunogenetics	NULL
,	NULL
New	NULL
York	NULL
.	NULL

p.	NULL
325-340	NULL
.	NULL

Ledbetter.J.A..	NULL
Shu.G.L	NULL
.	NULL

and	NULL
Clark.E.A	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Monoclonal	NULL
antibodies	NULL
to	NULL
a	NULL
new	NULL
39-13	NULL
kDa	NULL
B	NULL
cell-associated	NULL
cluster	NULL
group	NULL
modulate	NULL
B	NULL
cell	NULL
proliferation	NULL
.	NULL

In	NULL
MacMichael.A.J	NULL
.	NULL

(	NULL
ed	NULL
.	NULL
)	NULL

.	NULL

Leucocyte	NULL
Typing	NULL
IIL	NULL
,	NULL
White	NULL
Cell	NULL
Differentiation	NULL
Antigens	NULL
.	NULL

Oxford	NULL
University	NULL
Press	NULL
,	NULL
Oxford	NULL
,	NULL
UK	NULL
.	NULL

p.	NULL
339-340	NULL
.	NULL

Lee.G	NULL
.	NULL

and	NULL
Gilman.M	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Dual	NULL
modes	NULL
of	NULL
control	NULL
of	NULL
c-fos	NULL
mRNA	NULL
induction	NULL
by	NULL
intracellular	NULL
calcium	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol..	NULL
14	NULL
.	NULL

4579-1587	NULL
.	NULL

Leprince.C..	NULL
Draves.K.E..	NULL
Geahlen.R.L..	NULL
Ledbetter.J.A	NULL
.	NULL

and	NULL
Clark.E.A	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
CD22	NULL
associates	NULL
with	NULL
the	NULL
human	NULL
surface	NULL
Ig	NULL
M-B-cell	NULL
antigen	NULL
receptor	NULL
complex	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
90	NULL
,	NULL
3236-3240	NULL
.	NULL

Livingstone.C..	NULL
Patel.G	NULL
.	NULL

and	NULL
Jones.N	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
ATF-2	NULL
contains	NULL
a	NULL
phosphorylation-dependent	NULL
transcriptional	NULL
activation	NULL
domain	NULL
.	NULL

EMBO	NULL
.	NULL

J..	NULL
14	NULL
,	NULL
1785-1797	NULL
.	NULL

Marais.R..	NULL
Wynne.J	NULL
.	NULL

and	NULL
Treisman.R	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
The	NULL
SRF	NULL
accessory	NULL
protein	NULL
Elk-1	NULL
contains	NULL
a	NULL
growth	NULL
factor-regulated	NULL
transcriptional	NULL
activation	NULL
domain	NULL
.	NULL

Cell	NULL
.	NULL

73	NULL
.	NULL

381-393	NULL
.	NULL

Minden.A..	NULL
Lin.A	NULL
.	NULL

,	NULL
McMahon.M	NULL
.	NULL

,	NULL
Lange.C.C..	NULL
Dérijard.B..	NULL
Davis.R.J..	NULL
Johnson.G.L	NULL
.	NULL

and	NULL
Karin.M	NULL
.	NULL

(	NULL
1994a	NULL
)	NULL
Differential	NULL
activation	NULL
of	NULL
ERK	NULL
and	NULL
JNK	NULL
mitogen-activated	NULL
protein	NULL
kinases	NULL
by	NULL
Raf-l	NULL
and	NULL
MEKK	NULL
.	NULL

Science	NULL
.	NULL

266	NULL
.	NULL

1719-1723	NULL
.	NULL

Minden.A..	NULL
Lin.A..	NULL
Smeal.T..	NULL
Dérijard.B..	NULL
Cobb.M..	NULL
Davis.R	NULL
.	NULL

and	NULL
Karin.M	NULL
.	NULL

(	NULL
1994b	NULL
)	NULL
c-Jun	NULL
N-terminal	NULL
phosphorylation	NULL
correlates	NULL
with	NULL
activation	NULL
of	NULL
the	NULL
JNK	NULL
subgroup	NULL
but	NULL
not	NULL
the	NULL
ERK	NULL
subgroup	NULL
of	NULL
mitogen-activated	NULL
protein	NULL
kinases	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol..	NULL
14	NULL
,	NULL
6683-6688	NULL
.	NULL

Mosialos.G..	NULL
Birkenbach.M..	NULL
Yalamanchili.R..	NULL
VanArsdale.T..	NULL
Ware.C	NULL
.	NULL

and	NULL
Kieff.E	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
The	NULL
Epstein-Barr	NULL
virus	NULL
transforming	NULL
protein	NULL
LMP	NULL
1	NULL
engages	NULL
signaling	NULL
proteins	NULL
for	NULL
the	NULL
tumor	NULL
necrosis	NULL
factor	NULL
receptor	NULL
family	NULL
.	NULL

Cell	NULL
,	NULL
80	NULL
,	NULL
389-399	NULL
.	NULL

Noelle.R.J..	NULL
Roy.M..	NULL
Shepherd.D.M..	NULL
Stamenkovie.L..	NULL
Ledbetter.J	NULL
.	NULL

A.	NULL
and	NULL
Aruffo.A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
A	NULL
39-kDa	NULL
protein	NULL
on	NULL
activated	NULL
helper	NULL
T	NULL
cells	NULL
binds	NULL
CD40	NULL
and	NULL
transduces	NULL
the	NULL
signal	NULL
for	NULL
cognate	NULL
activation	NULL
of	NULL
B	NULL
cells	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
89	NULL
.	NULL

6550-6554	NULL
.	NULL

Parry.S.L..	NULL
Hasbold.J..	NULL
Holman.M	NULL
.	NULL

and	NULL
Klaus	NULL
,	NULL
G.G	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Hypercross-linking	NULL
surface	NULL
IgM	NULL
or	NULL
IgD	NULL
receptors	NULL
on	NULL
mature	NULL
B	NULL
cells	NULL
induces	NULL
apoptosis	NULL
that	NULL
is	NULL
reversed	NULL
by	NULL
costimulation	NULL
with	NULL
IL-4	NULL
and	NULL
anti-CD40	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
152	NULL
,	NULL
2821-2829	NULL
.	NULL

Paulie.S..	NULL
Ehlin	NULL
,	NULL
H.B	NULL
.	NULL

,	NULL
Mellstedt.H	NULL
.	NULL

,	NULL
Koho.H..	NULL
Ben.A.H	NULL
.	NULL

and	NULL
Perlmann	NULL
,	NULL
P	NULL
.	NULL

(	NULL
1985	NULL
)	NULL
A	NULL
p50	NULL
surface	NULL
antigen	NULL
restricted	NULL
to	NULL
human	NULL
urinary	NULL
bladder	NULL
carcinomas	NULL
and	NULL
B	NULL
lymphocytes	NULL
.	NULL

Cancer	NULL
Immunol	NULL
.	NULL

Immunother..	NULL
20	NULL
.	NULL

23-28	NULL
.	NULL

Pessara.U	NULL
.	NULL

and	NULL
Koch.N	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Tumor	NULL
necrosis	NULL
factor	NULL
alpha	NULL
regulates	NULL
expression	NULL
of	NULL
the	NULL
major	NULL
histocompatibility	NULL
complex	NULL
class	NULL
H-associated	NULL
invariant	NULL
chain	NULL
by	NULL
binding	NULL
of	NULL
an	NULL
NF-kappa	NULL
B-like	NULL
factor	NULL
to	NULL
a	NULL
promoter	NULL
element	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol..	NULL
10	NULL
,	NULL
4146-4154	NULL
.	NULL

Pinchuk	NULL
,	NULL
L.M	NULL
.	NULL

,	NULL
Polacino.P	NULL
.	NULL

$	NULL
..	NULL
Agy.M.B..	NULL
Klaus.S.J	NULL
.	NULL

and	NULL
Clark	NULL
,	NULL
E.A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
The	NULL
role	NULL
of	NULL
CD40	NULL
and	NULL
CD80	NULL
accessory	NULL
cell	NULL
molecules	NULL
in	NULL
dendritic	NULL
cell-dependent	NULL
HIV-1	NULL
infection	NULL
.	NULL

/mmunity	NULL
,	NULL
1	NULL
,	NULL
317-325	NULL
.	NULL

Rafiee	NULL
,	NULL
P.	NULL
,	NULL
Lee	NULL
.	NULL

J.K.	NULL
,	NULL
Leung.C.-C.	NULL
and	NULL
Raffin.T.A	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
TNF-	NULL
induces	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
mitogen-activated	NULL
protein	NULL
kinase	NULL
in	NULL
adherent	NULL
human	NULL
neutrophils	NULL
.	NULL

J	NULL
.	NULL

/mmunol	NULL
.	NULL

,	NULL
154	NULL
,	NULL
4785-4792	NULL
.	NULL

Ren.C.L	NULL
.	NULL

,	NULL
Morio.T..	NULL
Fu.S.F	NULL
.	NULL

and	NULL
Geha.R.S	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Signal	NULL
transduction	NULL
via	NULL
CD40	NULL
involves	NULL
activation	NULL
of	NULL
lyn	NULL
kinase	NULL
and	NULL
phosphatidylinositol-3-kinase	NULL
.	NULL

and	NULL
phosphorylation	NULL
of	NULL
phospholipase	NULL
Cy2	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med..	NULL
179	NULL
.	NULL

673-680	NULL
.	NULL

Rothe.M..	NULL
Wong.S.C..	NULL
Henzel	NULL
.	NULL

and	NULL
Goeddel.D.V	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
A	NULL
novel	NULL
family	NULL
of	NULL
putative	NULL
signal	NULL
transducers	NULL
associated	NULL
with	NULL
the	NULL
cytoplasmic	NULL
domain	NULL
of	NULL
the	NULL
75	NULL
kDa	NULL
tumor	NULL
necrosis	NULL
factor	NULL
receptor	NULL
.	NULL

Cel/	NULL
.	NULL

78	NULL
,	NULL
681-692	NULL
.	NULL

Sanchez.L..	NULL
Hughes.R.T..	NULL
Mayer.B.J..	NULL
Yee.K..	NULL
Woodgett.J.R..	NULL
Avruch.J..	NULL
Kyriakis.J.M	NULL
.	NULL

and	NULL
Zon.LI	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Role	NULL
of	NULL
SAPK/ERK	NULL
kinase-1	NULL
in	NULL
the	NULL
stress-activated	NULL
pathway	NULL
regulating	NULL
transcription	NULL
factor	NULL
c-Jun	NULL
.	NULL

Nature	NULL
,	NULL
372	NULL
,	NULL
794-798	NULL
.	NULL

Schriever.F..	NULL
Freedman.A.S	NULL
.	NULL

,	NULL
Freeman	NULL
,	NULL
G..	NULL
Messner.E..	NULL
Lee.G	NULL
.	NULL

,	NULL
Daley.J	NULL
.	NULL

and	NULL
Nadler.L.M	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Isolated	NULL
human	NULL
follicular	NULL
dendritic	NULL
cells	NULL
display	NULL
a	NULL
unique	NULL
antigenic	NULL
phenotype	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med..	NULL
169	NULL
.	NULL

2043-2058	NULL
.	NULL

Siebeli.F..	NULL
Berberich.L	NULL
.	NULL

and	NULL
Clark.E.A	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Immediate	NULL
early	NULL
(	NULL
IE	NULL
)	NULL
gene	NULL
Cross-linking	NULL
CD40	NULL
activates	NULL
SAPK	NULL
expression	NULL
after	NULL
crosslinking	NULL
CD40	NULL
vs.	NULL
sigM	NULL
receptors	NULL
on	NULL
B	NULL
cells	NULL
.	NULL

Ninth	NULL
International	NULL
Congress	NULL
on	NULL
Immunology	NULL
.	NULL

Abstr	NULL
.	NULL

4046	NULL
,	NULL
p.	NULL
682	NULL
.	NULL

Sluss	NULL
,	NULL
HK	NULL
.	NULL

,	NULL
Barrett.T..	NULL
Dérijard.B	NULL
.	NULL

and	NULL
Davis.R.J	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Signal	NULL
transduction	NULL
by	NULL
tumor	NULL
necrosis	NULL
factor	NULL
mediated	NULL
by	NULL
JNK	NULL
protein	NULL
kinases	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol..	NULL
14	NULL
.	NULL

8376-8384	NULL
.	NULL

Smith.C.A..	NULL
Farrah.T	NULL
.	NULL

and	NULL
Goodwin.R.G	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
The	NULL
TNF	NULL
receptor	NULL
superfamily	NULL
of	NULL
cellular	NULL
and	NULL
viral	NULL
proteins	NULL
:	NULL
activation	NULL
.	NULL

costimulation	NULL
,	NULL
and	NULL
death	NULL
.	NULL

Cell	NULL
.	NULL

76	NULL
.	NULL

959-962	NULL
.	NULL

Su.B..	NULL
Jacinto.E	NULL
.	NULL

,	NULL
Hibi	NULL
.	NULL

M..	NULL
Kallunki.T..	NULL
Karin.M	NULL
.	NULL

and	NULL
Ben.N.Y	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
JNK	NULL
is	NULL
involved	NULL
in	NULL
signal	NULL
integration	NULL
during	NULL
costimulation	NULL
of	NULL
T	NULL
lymphocytes	NULL
.	NULL

Cell	NULL
,	NULL
77	NULL
,	NULL
727-736	NULL
.	NULL

Torres.R.M	NULL
.	NULL

and	NULL
Clark.E.A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Differential	NULL
increase	NULL
of	NULL
an	NULL
alternatively	NULL
polyadenylated	NULL
mRNA	NULL
species	NULL
of	NULL
murine	NULL
CD40	NULL
upon	NULL
B	NULL
lymphocyte	NULL
activation	NULL
.	NULL

J	NULL
.	NULL

/mmunol..	NULL
148	NULL
,	NULL
620-626	NULL
.	NULL

Tsubata.T..	NULL
WuJ	NULL
.	NULL

and	NULL
Honjo.T	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
B-cell	NULL
apoptosis	NULL
induced	NULL
by	NULL
antigen	NULL
receptor	NULL
crosslinking	NULL
is	NULL
blocked	NULL
by	NULL
a	NULL
T-cell	NULL
signal	NULL
through	NULL
CD40	NULL
.	NULL

Nature	NULL
,	NULL
364	NULL
,	NULL
645-648	NULL
.	NULL

Uckun	NULL
,	NULL
F.M..	NULL
Schieven.G.L..	NULL
Dibirdik.1..	NULL
Chandan	NULL
,	NULL
L.M	NULL
.	NULL

,	NULL
Tuel.A.L	NULL
.	NULL

and	NULL
Ledbetter.J.A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Stimulation	NULL
of	NULL
protein	NULL
tyrosine	NULL
phosphorylation	NULL
,	NULL
phosphoinositide	NULL
turnover	NULL
,	NULL
and	NULL
multiple	NULL
previously	NULL
unidentified	NULL
serine/	NULL
threonine-specific	NULL
protein	NULL
kinases	NULL
by	NULL
the	NULL
Pan-B-cell	NULL
receptor	NULL
CD40/	NULL
Bp50	NULL
at	NULL
discrete	NULL
developmental	NULL
stages	NULL
of	NULL
human	NULL
B-cell	NULL
ontogeny	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem..	NULL
266	NULL
,	NULL
17478-17485.	NULL
van	NULL
Dam.H..	NULL
Duyndam.M..	NULL
Rottier	NULL
,	NULL
R..	NULL
Bosch.A..	NULL
de	NULL
Vries-Smits	NULL
,	NULL
L.	NULL
,	NULL
Herrlich	NULL
,	NULL
P.	NULL
,	NULL
Zantema.A..	NULL
Angel.P	NULL
.	NULL

and	NULL
van	NULL
der	NULL
Eb.AJ	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Heterodimer	NULL
formation	NULL
of	NULL
cJun	NULL
and	NULL
ATF-2	NULL
is	NULL
responsible	NULL
for	NULL
induction	NULL
of	NULL
c-jun	NULL
by	NULL
the	NULL
243	NULL
amino	NULL
acid	NULL
adenovirus	NULL
EIA	NULL
protein	NULL
.	NULL

EMBO	NULL
J..	NULL
12	NULL
.	NULL

479-487.	NULL
van	NULL
Dam.H..	NULL
Wilhelm.D..	NULL
Herr.1..	NULL
Steffen.A	NULL
.	NULL

,	NULL
Herrlich.P	NULL
.	NULL

and	NULL
Angel.P	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
ATF-2	NULL
is	NULL
preferentially	NULL
activated	NULL
by	NULL
stress-activated	NULL
protein	NULL
kinases	NULL
to	NULL
mediate	NULL
c-/wn	NULL
induction	NULL
in	NULL
response	NULL
to	NULL
genotoxic	NULL
agents	NULL
.	NULL

EMBO	NULL
J..	NULL
14	NULL
.	NULL

1798-1811	NULL
.	NULL

Xu.J..	NULL
Foy.T.M..	NULL
Laman	NULL
,	NULL
J.D..	NULL
Elliot	NULL
.	NULL

W.A..	NULL
Dunn	NULL
J.J..	NULL
Waldschmidt.T.J..	NULL
Elsemore.J..	NULL
Noelle.R.J	NULL
.	NULL

and	NULL
Flavell.R.A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Mice	NULL
deficient	NULL
for	NULL
the	NULL
CD40	NULL
ligand	NULL
.	NULL

Immunity	NULL
.	NULL

1	NULL
,	NULL
423-431	NULL
.	NULL

Yan.M..	NULL
Dai.T	NULL
.	NULL

,	NULL
Deak.J.C..	NULL
Kyriakis.J.M..	NULL
Zon.L.I	NULL
.	NULL

,	NULL
Woodgett.J.R	NULL
.	NULL

and	NULL
Templeton.D.J	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Activation	NULL
of	NULL
stress-activated	NULL
protein	NULL
kinase	NULL
by	NULL
MEKKI	NULL
phosphorylation	NULL
of	NULL
its	NULL
activator	NULL
SEK1	NULL
.	NULL

Nature	NULL
,	NULL
372	NULL
,	NULL
798-800	NULL
.	NULL

Received	NULL
on	NULL
June	NULL
28	NULL
,	NULL
1995	NULL
;	NULL
revised	NULL
on	NULL
September	NULL
1	NULL
,	NULL
1995	NULL
101	NULL

